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Regulatory Mechanism of Myeloid Derived Suppressor Cell Activity 
 
Cesar Alexander Corzo 
 
ABSTRACT 
 
Myeloid-derived suppressor cells (MDSC) are a major component of the immune 
suppressive network that develops during cancer. MDSC down-regulate immune 
surveillance and antitumor immunity and facilitate tumor growth. The ability of MDSC 
to suppress T cell responses has been documented; however the mechanisms regulating 
this suppression remain to be understood. This work proposes a biological dichotomy of 
MDSC regulated by the tumor microenvironment. In peripheral lymphoid organs MDSC 
cause T-cell non-responsiveness that is antigen-specific. These MDSC have increased 
expression of NOX2, enabling them to produce large amounts of reactive oxygen species. 
Since the transcription factor STAT3 is substantially activated in MDSC, its potential 
role in upregulation of NOX2 expression was investigated. Over-expression of a 
constitutively active form of STAT3 increases expression of NOX2 subunits, whereas 
attenuation of STAT3 activity leads to decreased expression of NOX2. The significance 
of NOX2 in ROS generation is demonstrated in mice devoid of NOX2 function; NOX2-
deficient MDSC are unable to inhibit antigen-induced activation of T cells. In contrast, 
MDSC within the tumor microenvironment have a diminished potential to generate ROS 
but acquire expression of arginase and inducible nitric oxide synthase, enzymes 
  
 
 
vi 
implicated in T cell non-responsiveness. Upregulation of these enzymes results in MDSC 
ability to inhibit lymphocyte response in absence of antigen presentation. The tumor 
microenvironment also promotes the differentiation of MDSC to tumor associated 
macrophages. 
Hypoxia is an exclusive feature to the tumor microenvironment and we 
investigated its involvement in the properties of MDSC at the tumor site. Exposure of 
spleen MDSC to hypoxia converts MDSC to non-specific suppressors and induces a 
preferential differentiation to macrophages. Stabilization of HIF-1!, a transcription factor 
activated by hypoxia, induces similar changes in MDCS as hypoxic exposure. Finally, 
ablation of HIF-1! prevents MDSC from acquiring factors that enable the suppression of 
T cells in absence of antigen. These findings help to expand our understanding of the 
biology of MDSC and suggest a regulatory pathway of myeloid cell function exclusive to 
the tumor microenvironment. They may also open new opportunities for therapeutic 
regulation as we now should take into consideration how systemic location affects the 
function of MDSC.  
 
 1 
 
 
 
INTRODUCTION 
 
Cancer and the Immune System 
Cancer is among the most life-threatening diseases and has risen to become the 
second leading cause of death in the developed world. Most cancer patients are treated by 
a combination of surgery, radiation, and/or chemotherapy. While these standard therapies 
are efficient at treating the primary tumor, cancer still causes 25% of mortalities in the 
industrialized world. The primary reason for the failure in mortality prevention is the 
ineffectiveness of traditional treatments in controlling metastatic spread of the disease.  
Deficiencies in immune responses have been extensively described in cancer 
patients. The observation that tumor-infiltrating lymphocytes (TILs) and antigen 
presenting cells (APCs) are non-functional in tumor tissues exemplifies the defects in the 
immune system (1-5). Decreased numbers of mature dendritic cells (DCs) have been 
observed in the lymph nodes and spleen of tumor-bearing mice (1,2,3), and in peripheral 
blood of cancer patients (4). In addition to the DC defects, T cells are rendered tolerant to 
tumor antigens early during tumor progression (5) demonstrating that the T lymphocyte 
compartment also becomes systemically impaired.  
The failure of the immune system to eradicate tumor cells is arguably due to its 
inability to recognize cancer cells in an immunogenic context. However, it was shown 
over a century ago that activation of the immune system using the highly immunogenic 
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Coley’s toxin induced a potent systemic inflammatory response that helped to control 
tumor growth and in some cases to eradicate solid tumors (6), demonstrating that if 
properly activated the immune system is capable of controlling and eliminating the 
disease. This concept helped establish the immunotherapy approach for cancer treatment. 
The purpose of cancer immunotherapy is to activate the immune system and to restore its 
functionality, hoping that it will be able to eliminate the primary tumor and prevent its 
metastatic spread.  
Current therapies intended to boost the immune system involve administration of 
cytokines: interleukin-2 (IL-2) and interferon alpha (IFN-!) are FDA-approved for 
treatment of Kaposi’s sarcoma and multiple types of leukemia (7, 8). A second approach 
of immunotherapy involves antibody-based treatment: Rituxan, Herceptin, Campath are 
example of commercially antibodies available for treatment of various leukemias, non-
Hodgkin’s lymphoma, and colorectal cancer (9). Cancer vaccines are the latest strategy 
for prevention and treatment ofcancer. Cancer vaccines are intended to induce an 
endogenous, long-lasting tumor antigen-specific immune response. They involve the 
processing of tumor antigens by APCs and the accompanying presentation to T cells. 
Cancer vaccines include protein-containing vaccines, in which tumor-associated antigens 
(10) are usually combined with either adjuvants to induce a strong immune response, 
with irradiated autologous tumor cells, or with allogenic tumor cells lines transfected 
with cytokine genes (e.g. GM-CSF, IL2). Additionally, DC-based vaccines are currently 
under evaluation. Autologous DCs are activated in vitro, provided with the tumor-antigen 
(either as peptide, or as mRNA or cDNA encoding the antigen), and re-injected into the 
patient. DC-based vaccines have shown promising results in animal models and in the 
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clinical setting. 
The success of cancer vaccines is partly restrained by the accumulation of a group 
of myeloid cells with immune suppressive activity. These cells can take up antigen 
delivered by vaccination, present it to activated T cells and thereby inhibit the same 
antigen-specific T cells that the vaccination strategy is aiming to activate (11). This 
makes even the most effective antigen-delivery strategy ineffective because cancer 
patients or animals can have considerable numbers of these myeloid-derived suppressor 
cells. Reducing the numbers of these suppressive cells and/or inhibiting their suppressive 
factors have been demonstrated to improve the efficacy of immunotherapy in both animal 
models and cancer patients (12). This inhibitory population presents one of the many 
roadblocks to the success of cancer immunotherapy and their elimination is a priority for 
cancer patients who are candidates for active immunotherapy.  
 
Identification and Definition of MDSC 
A suppressive myeloid cell population associated with tumor development and 
immunosuppression was described three decades ago (13). The first reports demonstrated 
that administration of a Gr-1 specific antibody slowed the growth of an experimental 
tumor. It was later found that the Gr-1 antibody eliminated both polymorphonuclear and 
mononuclear cells in the blood. The Gr-1+ cells were comprised of cells at different 
stages of maturation along the myeloid differentiation pathway (14). This suppressive 
population is referred to as myeloid-derived suppressor cells (MDSC). MDSCs are 
characterized in mice by the co-expression of the myeloid-cell lineage differentiation 
antigen Gr1 and CD11b, also known as !M-integrin (14, 15). Gr-1+CD11b+ cells are 
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normally present in the bone marrow of healthy mice and accumulate in the spleen and 
blood of tumor bearing mice (16–19). MDSCs lack the expression of cell-surface markers 
that are specifically expressed by monocytes, macrophages or DCs, and comprise a 
mixture of immature myeloid cells (IMC) that have the morphology of granulocytes or 
monocytes and have been prevented from fully differentiating into mature cells (20). Gr-
1+CD11b+ IMC present in steady-state conditions are not able to induce suppression of 
stimulated T cells, and in healthy animals, they can quickly differentiate into mature 
granulocytes, macrophages or dendritic cells (DCs). Normal mouse bone marrow 
contains 20–30% of cells with this phenotype, but these cells make up only a small 
proportion (2–4%) of spleen cells and are absent from the lymph nodes. In tumor-bearing 
animals, cells with this phenotype can make up 50-70% of all bone marrow cells and up 
to 40% of all splenocytes (these percentages fluctuate in tumor models). The human 
equivalents of mouse MDSC are most commonly defined as CD14–CD11b+CD33+ cells 
or, more narrowly, as cells that express the common myeloid marker CD33 but lack the 
expression of markers of mature myeloid and lymphoid cells, and of the MHC class II 
molecule HLA-DR (21,22). In healthy individuals, IMCs constitute ~0.5% of peripheral 
blood mononuclear cells (22); in the blood of patients with different types of cancer a 
tenfold increase in MDSC numbers has been detected (21-24).  
Although initial observations of MDSC expansion were made in the field of 
cancer, an expansion of immunosuppressive myeloid cell population has been 
documented in multiple pathological inflammatory conditions. The importance of MDSC 
has transcended into other scientific fields and MDSC-related research has extended to 
areas involving bacterial infections (25,31), parasitic infections (26-30), traumatic stress, 
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transplantation and autoimmunity (32-33).  
 
MDSC Expansion in Cancer 
The past decade of research has failed to identify a single factor responsible for 
expansion of MDSC. The expansion of MDSC is predominantly viewed as the result of 
the combined effort of many different factors, including pro-inflammatory mediators. The 
contribution of inflammation to tumor initiation and progression is an old concept. It was 
proposed by pathologist Rudolf Virchow over 140 years ago (34). Evidence linking 
inflammation and cancer comes from studies demonstrating that long-term users of 
nonsteroidal anti-inflammatory drugs, including aspirin, are at a significantly lower risk 
of developing colorectal (35), lung, stomach, esophageal (36), and breast (37) cancers. In 
addition, the block of inflammatory mediators or signaling pathways regulating 
inflammation reduces tumor incidence and delays tumor growth, whereas heightened 
levels of proinflammatory mediators or adoptive transfer of inflammatory cells increases 
tumor development (38). These observations support the notion of a causative 
relationship between chronic inflammation and cancer onset and progression. The list of 
inflammatory mediators implicated in MDSC expansion includes the complement protein 
C5a, prostaglandins PGE2, and the family of calcium binding proteins S100A8/A9.  
The anaphylatoxin C5a is a complement component and a potent chemoattractant 
and inflammatory mediator. Studies with C5aR-deficient mice demonstrate the 
contribution of C5a to tumor progression, as after tumor challenge C5aR-/- had lower 
tumor volumes than littermate controls (38). C5a promotes the accumulation of MDSC 
not only in tumor tissues, but in peripheral lymphoid organs as well. The ability to 
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suppress T cells of MDSC from tumor-bearing C5aR-deficient was impaired and 
consequently, tumor-bearing C5aR-/- had higher numbers of infiltrating CTLs in the 
tumor tissue than wild type counterparts (38). A second set of potent inflammatory 
mediators produced by many tumors and implicated in MDSC expansion are the PGE2 
molecules. PGE2 synthesis begins with the COX-2 catalyzation of arachidonic acid to 
prostaglandin G2 (PGG2), which is subsequently modified by PGE synthase to PGE2. 
Mouse MDSC were shown to express all four PGE receptors and coculture of bone 
marrow progenitors with receptor agonists induced the differentiation of precursors cells 
into suppressive MDSC. Blocking the PGE2 pathway with COX-2 inhibitors in tumor-
bearing mice decreases the numbers of MDSC and delays progression of spontaneous 
mammary carcinomas (39).  
Myeloid progenitors express receptors for the S100 family members and 
accumulating evidence confirms their role in MDSC expansion during infection and 
inflammation. The S100 calcium-binding protein family comprises of 12 proteins that 
serve as inflammatory mediators released by cells of myeloid origin. S100A8 and 
S100A9 have been implicated in MDSC expansion. These proteins are released in 
response to cell damage, infection, or inflammation, and function as pro-inflammatory 
danger signals. When wild type mice were injected with complete Freud’s adjuvant 
(CFA), a fivefold increase in the proportion of circulating MDCS was observed between 
days 6 and 9 post-injection. In contrast, in S100A9 deficient mice, the number of 
circulating MDSCs did not increase after the treatment and the proportion of MDSC in 
the spleens of S100A9-/- mice after CFA challenge was threefold lower than challenged 
wild type animals (40).  
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S100 proteins-binding to their receptors activates nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) in MDSC (41), and a potential function of 
NF-KB in MDSC development has been proposed in microbial infections, during which 
accumulation of MDSC appears to result from Toll-like receptor (TLR) signaling. A 
recent study focused on polymicrobial sepsis in mice, induced by ligation of the cecum 
and a double enterotomy, found dramatic MDSC accumulating in spleens and peripheral 
lymph nodes after the procedure. MDSC accumulation did not occur in mice deficient for 
MyD88, an adapter protein operating downstream of TLRs (except TLR 3) that transmits 
signaling from the receptors. The ultimate target of MyD88 is the activation of NF-kB, 
suggesting a possible involvement of NF-kB in the accumulation of MDSC, at least 
during infection and tissue damage (31).   
 In cancer, the expansion of MDSC has been primarily attributed to the numerous 
cytokines and growth factors produced by tumor cells. Primary evidence supporting this 
conclusion derives from studies revealing a decline of circulating MDSC after surgical 
resection of tumors, and by early experiments that showed that conditioned medium from 
tumor cells cultured in vitro prevented the differentiation of hematopoietic progenitor 
cells (HPC) into mature APCs (42, 43). The cytokines and growth factors implicated to 
MDSC expansion include stem cell factor (SCF), IL-1!, macrophage colony-stimulating 
factor (M-CSF), IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), 
vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-!), IL-
10, IL-12, and IL-13 (44). Most of these cytokines trigger signaling cascades that 
converge in a common signaling pathway, the Janus tyrosine kinase (JAK) protein family 
members and signal transducer and activator of transcription 3 (STAT3), which are 
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signaling molecules that are involved in cell survival, proliferation, differentiation and 
apoptosis (45). STAT3 is a member of the STAT family of transcription factors which 
consists of seven members: STAT-1, -2, -3, -4, -6, and the closely related STAT5A and 
STAT5B (46-48). Engagement of cytokine receptors activates JAKs which subsequently 
recruit and phosphorylate STAT members. STATs undergo homo- or hetero- 
dimerization with other STAT proteins followed by translocation to the nucleus. STATs 
modulate the expression of genes involved in cell growth, survival and differentiation.  
Abnormal activation of STAT3 during tumor progression is well documented. 
STAT3 is constitutively activated in tumor cells (49) and in diverse tumor-infiltrating 
immune cells (50), leading to inhibition of proinflammatory cytokine, reduced chemokine 
production, and to the release of factors that downregulate the immune response. Hyper 
activation of STAT3 is also observed in MDSCs from tumor-bearing mice (51), and its 
persistent activation preventing myeloid progenitors from differentiating. An in vitro 
study showed that exposure of hematopoietic progenitor cells (HPCs) to supernatants 
from tumor-cell cultures results in the accumulation of Gr-1+CD11b+ MDSC and 
diminution of mature DCs. Blocking of STAT3 activity in the HPCs restored their ability 
to differentiate into mature DCs. These findings were further confirmed in vivo (40). 
Thus, hyper-activation of STAT3 in MDSC promotes their expansion in tumor-bearing 
animals; however other potential outcomes stemming from STAT3 signaling in MDSC 
remain to be elucidated.  
 
Suppressive Mechanisms of MDSC 
MDSC-mediated suppression of T cell activation has been extensively studied and 
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proven by many research groups. These immunosuppressive activities appear to require 
direct contact with the target cell, suggesting that these suppressive activities function 
through cell-surface receptors and/or through the release of short-lived soluble mediators. 
Factors implicated in suppression of T-cell function include reactive oxygen species 
(ROS), regulation of L-arginine metabolism, production of TGF-!, depletion of cysteine, 
induction of T-regulatory cells (Treg), down regulation of L-selectin surface proteins on 
T cells and others. (18,82-85,94) 
1. ROS production 
 
Increased production of ROS is one of the main characteristics of MDSC 
(18,20,52-57). ROS are crucial immunosuppressive mediators; inhibition of ROS 
generation abrogates the suppressive function of MDSC in vitro (18,52,54). ROS are 
highly reactive molecules due to the presence of unpaired valence shell electrons. 
Generation of ROS occurs as the normal byproduct of oxygen metabolism and include 
such species as super oxide (O2-), hydrogen peroxide (H2O2), hydroxyl radical (OH-), 
hypochlorous acid (HOCl-), and peroxynitrite (ONOO-). Traditionally ROS are known 
for their propensity to cause oxidative damage to nucleic acids, proteins and lipids; this 
property is exploited by phagocytes to destroy invading pathogens. ROS also play a 
regulatory role in signal transduction and gene expression.  
The primary stimuli promoting ROS production in MDSC may be contact with 
other cells. One study demonstrated that cell-cell interactions mediated by the integrins 
CD11b, CD18 and CD29 significantly increased ROS production by MDSC (18). Thus, 
adhesion molecules may contribute to MDSC-generation of ROS. Our lab has 
demonstrated the significance of ROS generation by MDSC; the ROS molecule 
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peroxynitrite produced during direct contact with T cells resulted in nitration of the T-cell 
receptor and CD8 molecules, altering specific peptide binding and rendering T cells 
unresponsive to antigen-specific stimulation (12). Peroxynitrite is produced by the 
chemical reaction between nitric oxide (NO) and O2-; it is one of the most powerful 
oxidants that are produced in the body capable of inducing the nitration and nitrosylation 
of the amino acids cysteine, methionine, tryptophan and tyrosine (63).  
Although studies have suggested that ROS molecules are important factors in 
tumor-mediated immune suppression, the mechanism leading to generation of ROS by 
MDSC remains to be elucidated. The mitochondria and various oxidative enzymes can 
generate ROS. The main source of ROS in leukocytes is a multi-subunit enzyme called 
NADPH oxidase (NOX2), a complex that generates O2- in the one-electron reduction of 
O2 using electrons supplied by NADPH after activation of its various components (58). 
The oxidase complex consists of two membrane-bound proteins, gp91phox and p22phox,  
cytosolic components p47phox, p67phox, p40phox, and a small GTPase protein  Rac1 or Rac2 
(58). The phagocyte NOX2 plays a key role in innate immune responses against 
microbial pathogens by generating ROS that act as powerful microbicidal agents (59). 
Sustained NOX2 activity requires continuous renewal of the enzyme complex; without it 
rapid deactivation occurs (60). The activation of the complex, which is essential for its 
full functionality, requires phosphorylation of the cytosolic components and their 
translocation to the plasma membrane where the generation of O2- takes place (61). The 
assembly and activation of the NOX2 complex can be induced by pro-inflammatory 
cytokines, such as GM-CSF and TNF-alpha (62). Cell adhesion molecules and integrin 
engagement are also capable stimulants of NOX2-dependent ROS generation (160) 
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2. Metabolism of amino acid L-arginine 
Metabolism of the amino acid L-arginine has been implicated in the suppressive 
activity of MDSC. Metabolic manipulation of L-arginine is a survival strategy conserved 
in lower organisms (64). This strategy is exploited by MDSC to limit the expansion and 
function of T cells. L-arginine serves as a substrate for two distinct but related enzymes 
arginase and inducible nitric oxide synthase. 
A) Arginase (ARG): The importance of this enzyme in tumor progression is reflected by 
the observation that its inhibition slows the growth of a lung carcinoma in a dose-
dependent manner (65). Two distinct isoforms, Arg1 and Arg2, have been identified in 
mammals; they are encoded by different genes and are located in the cytoplasm and 
mitochondria, respectively. Arg1 is primarily located in the cytosol of hepatocytes and is 
an important component of the urea cycle. Arg1 expression is induced in myeloid cells by 
exposure to the Th2 cytokines IL-4 or IL-13 (66, 67), TGF-! (68), and GM-CSF (69). 
Arg2, also known as kidney-type arginase, is constitutively expressed in the mitochondria 
of various cell types, including renal cells, neurons, macrophages and enterocytes. 
Arginases hydrolyse the amino acid L-arginine to L-ornithine and urea. L-Ornithine is a 
precursor for the synthesis of polyamines by the ornithine decarboxylase (ODC) 
pathway; polyamines have an anti-inflammatory role and inhibit the release of pro-
inflammatory cytokines from monocytes (70).  
The primary consequence of arginase upregulation in MDSC is the depletion of 
L-arginine from their surroundings. In the absence of L-arginine, T cells cultured in vitro 
fail to proliferate upon stimulation and fail to produce interferon gamma (IFN-!) (71). L-
arginine deprivation triggers several negative effects on T cell activation. First, T cells 
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deprived of L-arginine are deficient for CD3! chain and become arrested in the Go–G1 
phase of the cell cycle (72). Second, the expression of cell cycle regulators cyclin D3 and 
cyclin-dependent kinase 4 is also compromised (73). Finally, L-arginine starvation can 
result in phosphorylation of eukaryotic translation initiation factor 2 (EIF2a), halting the 
initiation of translation and repressing protein synthesis (74).  
B) Nitric Oxide Synthase (NOS). L-arginine is also the substrate for a family of 
enzymes known as NOS. These enzymes catalyse the reaction between oxygen and L-
arginine, generating L-citrulline and NO. Three distinct isoforms of NOS are the products 
of different genes: NOS1 is primarily found in neuronal tissue; NOS2 is the inducible 
isoform (also known as iNOS) and is found in various cells of the immune system, 
including several types of myeloid cell. NOS3 is found in endothelial cells (75-77). 
NOS inhibitors reverse immune suppression demonstrating immunoregulatory 
properties of NO (78). NO operates through various mechanisms to suppress T cell 
function. It interferes with the IL-2R-signalling pathway by blocking the phosphorylation 
of signal-transducing pathways coupled to IL-2R and by altering the stability of IL-2 
mRNA (79). Exposure to NO can also lead to cellular apoptosis (80). NO also interferes 
with the cytotoxic effector phase (81). NO causes mRNA instability of Ras, a critical 
molecule in the signal transduction cascade from TCR activation to cytolytic granule 
release, resulting in inefficient exocytosis of the cytotoxic granules. Through this 
mechanism, NO prevents activated lymphocytes from killing target cells. 
3. Production of TGF-! 
The immunosuppressive molecule TGF-" has also been implicated to MDSC 
function. TGF-" is a cytokine with multiple immunosuppressive properties (82). 
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Inhibition of TGF-! by antibody or soluble receptor inhibits tumor growth in vivo (83) 
and T cells that do not respond to TGF-! were resistant to implanted tumor cell lines B16 
and EL4 (84). A separate study suggested that MDSC are the main source of TGF-! in 
tumor-bearing animals. In this study, MDSC induced by a mouse fibrosarcoma or colon 
carcinoma when stimulated with IL-13 through the IL-13R" are activated to produce 
TGF-! (85) In the presence of TGF-!1, antigen-stimulated T cells lose their cytolytic 
activity. This evidence suggests that direct action of TGF-! on T cells suppresses 
antitumor T cell activity and results in uncontrolled outgrowth of tumor cells. 
4. Cysteine depletion.  
A new proposed mechanism of immune regulation employed by MDSC is 
deprivation of the amino acid cysteine. Cysteine is essential for T cell activation. T 
lymphocytes lack the enzyme to generate cysteine and must import it from APCs during 
antigen presentation. Macrophages and DCs import cystine, a cysteine precursor, from 
their environment and metabolize it into cysteine. MDSC import cystine at comparable 
rates as APCs but are unable to export cysteine into their surroundings. Thus, through the 
competition for cystine, MDSC make their immediate environment cysteine-deficient and 
T cells are unable to synthesize the necessary proteins for activation (86) 
5. Induction of regulatory T cells 
MDSC-induction of forkhead box P3 (FOXP3)+ Tregs has been proposed to 
contribute to the persistent tolerance to tumor-specific antigens in tumor-bearing host. 
However, conflicting reports on this subject have been presented. In mice bearing 1D8 
ovarian tumours, the MDSC-mediated induction of Tregs required the expression of the co-
stimulatory B7 family member, B7H-1 (also known as CD80), by MDSCs (87). In a 
 14 
mouse model of lymphoma, MDSCs were shown to induce Tregs expansion through a 
mechanism that involved arginase 1 and the capture, processing and presentation of 
tumor-associated antigens by MDSCs, but was independent of TGF! (88). By contrast, 
another group found that the percentage of Treg was invariably high throughout tumour 
growth and did not relate to the kinetics of expansion of the MDSC population, 
suggesting that MDSCs were not involved in Tregs induction (89). Although it seems 
possible that MDSCs are involved in Tregs differentiation through production of cytokines 
or through direct cell–cell interactions, further work is required to resolve these 
conflicting reports and to determine the physiological relevance of these studies. 
6. Downregulation of L-selectin 
Antigen naïve T cells typically encounter antigen in draining lymph nodes and 
inside tumor tissues (90,91). T cells are directed to these sites because they express high 
levels of L-selectin (CD62L), a selectin family member that facilitates the extravasation 
of leukocytes from the blood and lymphatics to lymph nodes and inflammatory locales, 
such as tumor microenvironments (92,93). However, in cancer patients and animal 
models, circulating naïve lymphocytes typically express low levels of L-selectin. 
Evidence linking MDSC to the reduced levels of L-selectin include the inverse 
correlation of L-selectin expression in T cells with the number of MDSC in tumor 
bearing mice (94). Furthermore, CD4+ or CD8+ T cells co-cultured with MDSC had an L-
selectin low phenotype, demonstrating that MDSC directly down-regulate T cell 
expression of L-selectin. Hence, this study proposed that MDSC block T cell activation 
by inhibiting T cell trafficking to antigen-containing sites. 
  
Origin and Functional Polarization of TAM  
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In addition to MDSC, tumor-associated macrophages (TAMs) are a population of 
myeloid cells that negatively regulate antitumor immune responses. The relationship 
between TAMs and MDSCs is not completely defined but, as discussed below, TAMs 
have been suggested to partly derive from or be related to MDSCs. Numerous studies 
have found a direct correlation between the presence of macrophages in tumor tissues and 
poor prognosis in multiple mouse and human malignancies (95-98) making the presence 
of TAMs a key prognosticator of cancer progression. Our current knowledge regarding 
the origin of macrophages at the tumor site remains incomplete. The recruitment of 
monocytes to neoplastic tissues is a contributing factor to the accumulation of TAMs 
(98). Monocytes originate from the bone marrow and enter the circulation where they 
undergo maturation. Differentiation into macrophages happens once mature monocytes 
migrate into the tissues and involves a list of changes: the cell enlarges five- to ten-fold; 
phagocytic ability is enhanced; production of hydrolytic enzymes increases, and gains the 
potential to secrete large numbers of inflammatory factors (99).  
During the course of an immune response macrophages become activated and, 
depending on the cytokine network they encounter, become either highly effective in 
destroying potential pathogens and activating the adaptive immune system, or become 
attenuators of the inflammatory response. These two opposing polarization states are 
classified as M1 or M2 polarization. M1 macrophages, also known as classically 
activated macrophages, are powerful effectors against invading pathogens and tumor 
cells, secrete inflammatory cytokines and efficiently activate the Th1 response. M1 
macrophages are induced in response to IFN-! alone or together with microbial agents 
(i.e. LPS) (100). In contrast to M1 macrophages, the alternatively activated M2 
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macrophage is induced by anti-inflammatory molecules, such as cytokines IL-4, IL-13, 
IL-10 and glucocorticoids. M2 macrophages mediate wound repair, tissue remodeling, 
angiogenesis, and suppress Th1 immunity (101). While the M1 phenotype is 
characterized by production of cytokines IL-12, IL-6, TNF-!, the M2 macrophage 
classically produces IL-10 and TGF-". In addition to their distinct patterns of cytokine 
expression, metabolism of L-arginine is also a distinguishable characteristic of polarized 
macrophages: activation of NOS2 is a hallmark of M1 macrophages whereas ARG1 
activation is one of the most specific markers of M2 polarization.  
It has been suggested that macrophages differentiating within the 
immunosuppressive environment of a tumor display an M2-like phenotype, although it is 
not clear whether this suggestion can be generalized and applicable to TAMs in the 
different regions of a tumor. However, TAMs do appear to share a number of similarities 
with M2 macrophages include expression of immunosuppressive factors (IL-10, TGF-", 
ARG1) while producing low levels of M1 macrophage–mediated inflammation mediators 
i.e. IL-12, tumor necrosis factor alpha (TNF-!), IL-6, iNOS (102, 103, 104). 
Angiogenesis is an M2-associated function, and TAMs are associated with angiogenesis 
through the production of angiogenic factors (VEGF, CCL2, FGF2, CXCL8, CXCL1, 
and CXCL2) (102, 105, 106, 107). TAMs express high levels of the mannose receptor, a 
signature of M2 polarization. TAMs. TAMs are poor producers of both NO and ROS, 
hallmark characteristics of microbicidal M1 macrophages, and are poor antigen-
presenting cells. In addition, TAMs display several pro-tumoural functions and secrete 
factors that contribute to matrix remodeling (TGF-", CCL2, matrix metalloproteinases 
such as MMP9) (102, 108), and have been observed to recruit Tregs into tumor tissues 
 17 
(through secretion of CCL22) (109).  
Accumulation of TAMs in neoplastic tissues appears to be driven by the action of 
tumor-derived cytokines. VEGF and M-CSF promote monocytic migration and survival. 
IL-10 promotes monocyte differentiation into macrophages and blocks their 
differentiation to DCs. Additionally, chemokines produced by tumor cells (CCL2 being 
the most frequently found in tumors) appear to play a fundamental role in the recruitment 
of monocytes to the tumor site. Moreover, a relationship between MDSC and TAMs has 
also been suggested by recent studies; splenic Gr-1+ cells isolated from tumor-bearing 
animals transferred into new tumor-bearing hosts were shown to reach the tumor site and 
become TAMs characterized by high STAT1 phosphorylation and constitutive expression 
of ARG1 and NOS2 (78). This study indicates that, in addition to monocytes, circulating 
MDSC are plausible precursors of TAMs. 
 
Role of Hypoxia in Accumulation of TAMs 
Hypoxia is the state of oxygen deprivation and a characteristic feature of growing 
tumors. Hypoxic areas arise due to rapid oxygen-consumption rate by cancer cells along 
with insufficient oxygen supply. This disparity is caused partly when solid tumors rapidly 
outgrow their blood supply, leaving portions of the tumor with areas where the oxygen 
concentration is significantly lower than in healthy tissues. For instance, oxygen partial 
pressure (pO2) measurements in squamous cell carcinomas from cervical cancer patients 
showed a four-fold reduction compared to normal cervix tissue (8 mmHg in tumors, 42 
mmHg in normal cervix) (117). The difference in oxygen tension between tumor tissues 
and the circulation is even greater, as pO2 in alveoli reaches 100 mm Hg (118). The 
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oxygenation status and extent of hypoxia were independent of clinical size, tumor stage 
and grade of malignancy (117). 
Cells have developed mechanisms to cope with hypoxic stress. The principal 
element allowing cells to adapt to hypoxic stress is the hypoxia-inducible factor (HIF)-1. 
HIF1 is a heterodimeric transcription factor consisting of a constitutively expressed HIF-
1! subunit and the oxygen-tension-regulated HIF-1" subunit. In the presence of oxygen, 
the HIF1" protein is quickly targeted for ubiquitination and degradation but accumulates 
in response to declining oxygen levels (119,120). Increased HIF1" protein stability and 
activity of the HIF1 complex, in turn, regulate the transcription of a vast array of genes 
involved in tumor-cell survival: oxygen delivery, angiogenesis, and energy conservation 
(119,121). 
Macrophages are also affected by low oxygen tension. In mononuclear cells, 
hypoxia promotes production of growth factors and cytokines linked to tumor 
angiogenesis and progression. VEGF is one such example; interestingly, VEGF 
expression by TAMs is confined only to hypoxic areas in tumor sections and is not 
detected in well-vascularized sections (122). In vitro studies with macrophages cultured 
under hypoxia have shown their increased production of key proangiogenic growth 
factors (123,124). Hypoxia is also capable of modifying immune responses from 
macrophages, as various inflammatory and anti-inflammatory mediators are increased in 
macrophages after hypoxic exposure (125). Furthermore, the presence of TAMs in the 
tumor-microenvironment may be controlled in part by tumor hypoxia. Corroborating this 
hypothesis is the observation that TAMs primarily accumulate at highest densities in 
hypoxic areas of solid tumors, a phenomenon reported in breast (110), prostate (111) and 
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ovarian tumors (112). Chemoattractants released by tumor cells, such as endothelin-2 and 
EMAPII, have been associated with TAM recruitment to hypoxic sites (113). In addition, 
hypoxia impedes the motility of macrophage once they reach hypoxic areas by inducing 
down-regulation of chemokine receptors CCR2 and CCR5 (114,115) and up-regulation 
of the enzyme mitogen-activated protein kinase phosphatase (MKP-1) which inhibits 
chemotaxis signaling (116). 
Although there is plenty of information on the migration and activation of 
macrophages induced by hypoxia, the literature contains rather little of the effect of 
hypoxia on the differentiation of myeloid cells. Recently, hypoxia was reported to inhibit 
the maturation of bone marrow progenitors into functional DCs (126). This observation 
prompts the speculation that macrophage differentiation from progenitors could also be 
disturbed. Taking this idea further, it is quite plausible that tumor hypoxia may regulate 
the differentiation of MDSC into TAMs. 
 
Statement of Purpose 
The major goal of our laboratory is to understand the mechanisms of tumor-
associated immunosuppression and the development of new and effective cancer 
vaccines. MDSC is one of the major factors impeding host immune responses to tumor. 
These cells accumulate in peripheral lymphoid organs and in tumor tissues where they 
suppress the activation of T cells helping tumors avoid the effector arm of the adaptive 
immune system. The mechanisms of suppression traditionally ascribed to MDSC are 
enhanced ROS productivity and regulation of the amino acid L-arginine by its 
metabolizing enzymes Arg and iNOS. Although each pathway exerts different 
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consequences on T cell biology, both pathways converge on the same ultimate outcome: 
the inhibition of T cell function.  
The objective of this project was to determine the suppressive pathways by which 
MDSC render T cells ineffective in tumor bearing animals and cancer patients. The 
aspects investigated were the identification of suppressive nature of MDSC and its 
regulation, first in peripheral lymphoid organ and second in the tumor 
mocroenvironment. For MDSC-mediated T cell suppression in lymphoid organs, we 
focused on investigating increased ROS productivity in splenic MDSC, and whether 
STAT3 protein played a role in this modulation. For T cell suppression in the tumor 
microenvironment we concentrated on the ability of MDSC to modulate L-arginine 
metabolism and whether hypoxia, a prominent feature of tumor tissues, controlled the 
suppressive factors involved in MDSC-mediated suppression. Investigating the role of 
hypoxia led us to further dissect the role of HIF-1! in differentiation and expansion of 
MDSC in tumor-bearing hosts. 
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MATERIALS AND METHODS 
 
Mice and tumor models.  
BALB/c and C57BL/6 mice (6–8 wk of age) were obtained from the National 
Cancer Institute. Mice were kept in pathogen-free conditions. OT-1 TCR-transgenic mice 
(C57Bl/6-Tg(TCRaTCRb)1100mjb), gp91phox–/–(B6.129S6-Cybbtm1Din), CD45.1+ 
congeneic mice (B6.SJL-PtrcaPep3b/BoyJ), HIF-1!flox/flox (B6.129-Hif1atm3Rsjo/JE), 
and Mx1-Cre+/- (C57BL/6J-Tg(Mx1-cre)1Cgn/J) were purchased from Jackson 
Laboratories. 2C TCR transgenic mice have been described previously (10). STAT3-/- 
mice (LysMcre/Stat3flox/-) were generated by Dr. S. Akira (Osaka University, Japan). 
LysMcre mice were crossed with Stat3flox/+ mice to generate LysMcre/Stat3flox/- mice 
(experimental group). LysMcre/Stat3flox/+ mice from these crosses were used as littermate 
controls.  
The following subcutaneous tumor models were used in this study. In BALB/c mice: 
DA3 mammary carcinoma (provided by D. Lopez, University of Miami, FL), CT26 colon 
carcinoma (American Type Culture Collection (ATCC), Manassas, VA), and MethA 
sarcoma (provided by L. J. Old, Ludwig Institute for Cancer Research, New York, NY). 
In C57BL/6 mice: EL4 thymoma (ATCC), Lewis Lung Carcinoma (LLC), MC38 colon 
carcinoma (provided by I. Turkova, University of Pittsburgh, Pittsburgh, PA), and C3 
sarcoma (provided by W. Kast, University of Southern California, Los Angeles, CA). 
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The number of tumor cells injected s.c. was different for each model and was selected 
based on the ability to form a tumor with 1.5 cm diameter within 2-3 weeks of injection. 
EL-4 ascitic tumor was generated by injecting 3x105 tumor cells i.p. into C57BL/6 mice. 
mCC10TAg transgene model of lung cancer was described previously  (Magdaleno et al., 
1997). 
 
Reagents. 
Arginase inhibitor NW-hydroxyl-nor-L-arginine (nor-NOHA) and inducible NO 
synthase (iNOS) inhibitor NG-monomethyl-L-arginine (L-NMMA) were from 
Calbiochem. 2C-specific (H-2Kb, SIYRYYGL) and control (H-2Kb RAHYNIVTF) 
peptides were obtained from QCB. Dichlorodihydrofluorescein diacetate (DCFDA) was 
purchased from Molecular Probes (Eugene, OR). Anti-STAT3, phospho-STAT3 
antibodies were obtained from Cell Signaling Technology (Boston, MA); antibodies 
against gp91phox and p47phox were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA); anti- HIF-1! antibody from R&D systems; biotinylated anti-Gr-1 antibody from 
BD Pharmingen; biotinylated anti-F4/80 antibody from Serotec (Raleigh, NC). 
MiniMACS magnetic beads conjugated with streptavidin (Miltenyi Biotec, Auburn, CA). 
All other antibodies used for flow cytometry were purchased from BD Biosciences (San 
Jose, CA). 
 
Patients.  
Six patients (47-78 years old) with resectable T3 or T4 and N2b stage of head and 
neck cancer (HNC) were enrolled in the study after signing IRB approved consent. 
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Patients did not receive radiation or chemotherapy for at least 3 months prior to sample 
collection. Peripheral blood and tumor tissues were collected at the time of surgery from 
all patients. In order to obtain single cell suspensions from tumors, solid tissue was 
subjected to 1 hr enzymatic digestion using hyaluronidase (0.1 mg/ml; Sigma) 
collagenase (2 mg/ml; Sigma), DNase (600 U/ml; Sigma) and protease (0.2 mg/ml; 
Sigma) in RPMI 1640. The digested tissue was passed through a 70 !m mesh, 
erythrocytes removed by hypotonic lysis, and washed thoroughly to remove debris. 
Mononuclear cell suspensions were obtained from whole blood using a density gradient 
centrifugation.  All cell samples were analyzed within 3 hr following collection. Cells 
were loaded with DCFDA and stimulated with PMA where appropriate. To identify live 
MDSC, mononuclear cells were labeled with PerCP-Cy5.5-conjugated anti-CD14, APC-
conjugated anti-CD11b and PE-Cy-7-conjugated anti-CD33. Antibody labeled cells were 
finally resuspended in DAPI buffer to identify viable cells before data collection. To 
detect iNOS in MDSC, cells after surface staining with antibodies described above were 
fixed, permeabilized using FixPerm buffer (BD Biosciences), and then stained with FITC 
conjugated anti-iNOS antibody. Cells were evaluated by multi-color flow cytometry 
using a LSRII flow cytometer (BD Biosciences, Mountain View, CA). At least 100,000 
cells were collected from each parameter in order to obtain reliable data. Analysis of the 
samples was carried out essentially as described elsewhere (12). 
 
Cell culture and hypoxic conditions.  
MDSC were cultured in complete RPMI media containing 10 ng/mL GMCSF. 
Hypoxic environment (1% O2 with 5% CO2) was created and maintained using C-
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Chamber Hypoxic Incubator Chamber (BioSpherix, NY).   
 
Isolation of mouse cells.  
To collect MDSC, single cell suspensions were prepared from spleens, and red 
cells were removed using ammonium chloride lysis buffer. MDSC were isolated by cell 
sorting on a FACSAria cell sorter using staining with APC-conjugated anti-Gr-1 and PE-
conjugated anti-CD11b antibodies (BD Pharmingen). In some experiments splenic 
MDSC were isolated using magnetic beads conjugated with streptavidin (Miltenyi 
Biotec, Auburn, CA) and biotinylated anti-Gr-1 antibody. MDSC isolation from lung 
tumors. Lungs were collected from CC10Tg mice with lung tumor and the blood in the 
lungs was cleared by perfusion through the pulmonary artery with saline containing 2mM 
EDTA.  Lung tumor tissues were dissected and digested with collagenase XI (0.7 mg/ml; 
Sigma-Aldrich) and type IV bovine pancreatic DNase (30 mg/ml; Sigma-Aldrich) for 45 
min at 37°C water bath.  Remaining red cells were lysed by ACK and dead cells were 
removed by Lympholyte M.  Gr-1+ cells were isolated by using biotinylated anti-Gr-
1antibody and streptavidin microbeads on MiniMACS columns (MiltenyiBiotec, Auburn, 
CA). To collect peritoneal macrophages, mice were injected intraperitoneally (i.p.) with 
1 mL thiglycollate (DIFCO Laboratories, Detroit, MI). Three days later, peritoneal cells 
were obtained by peritoneal lavage. Peritoneal macrophages were harvested using 
biotinylated anti-F4/80 Ab (Serotec, Raleigh, NC)  and magnetic isolation. To harvest 
cells from ascitic tumors, mice were sacrificed and the peritoneum was washed with 10 
ml of ice-cold PBS; cells were then aspirated and placed on ice immediately.  
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ROS detection, arginase activity, and NO production.  
Oxidation-sensitive dye DCFDA was used to measure ROS production by 
MDSC. Cells were incubated at 37°C in RPMI in the presence of 2.5 µM DCFDA for 30 
min. For PMA-induced activation, cells were simultaneously cultured, along with 
DCFDA, with 30 ng/ml PMA (Sigma). Cells were then labeled with anti-Gr-1 and anti-
CD11b Abs on ice and evaluated by flow cytometry.  Production of H2O2 was quantified 
using Amplex® Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) as 
recommended by manufacturer. Briefly, 25 x 103 cells were resuspended in Hanks 
Balanced Salt Solution (Sigma). After addition of PMA (30 ng/ml), the absorbance at 560 
nm was measured using a microplate plate reader (Bio-Rad, Hercules, CA) at 37 °C. 
Absorbance results were normalized to a standard curve generated by serial dilutions of 
20 mM H2O2.  
Arginase activity was measured in cell lysates, as previously described (32). Briefly, cells 
were lysed for 30 min with 0.1% Triton X-100. To 100 µl of protein lysate (25 µg/ml), 
100 µl of 25 mM Tris-HCl and 10 µl of 10 mM MnCl2 were added, and the enzyme was 
activated by heating for 10 min at 56°C. Arginine hydrolysis was conducted by 
incubating the lysate with 100 µl of 0.5 M L-arginine (pH 9.7) at 37°C for 120 min. The 
reaction was stopped with 900 µl of H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7, v/v/v). The 
urea concentration was measured at 540 nm after addition of 40 µl of !-
isonitrosopropiophenone (dissolved in 100% ethanol), followed by heating at 95°C for 30 
min. One unit of enzyme activity is defined as the amount of enzyme that catalyzes the 
formation of 1 µmol urea per min. 
To detect nitrites equal volumes of culture supernatants (100 µl) were mixed with Greiss 
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reagent. After 10-min incubation at room temperature, the absorbance at 550 nm was 
measured using microplate plate reader (Bio-Rad). Nitrite concentrations were 
determined by comparing the absorbance values for the test samples to a standard curve 
generated by serial dilution of 0.25 mM sodium nitrite. 
 
Quantative Real-Time PCR (qRT-PCR) 
RNA was extracted with Trizol (Invitrogen, Frederick, MD); cDNA was 
synthesized and used for the evaluation of gene expression as described previously 
(Nefedova et al., 2004). To detect Arg1, iNOS, and NOX2 subunits, PCR was performed 
with 2 µl cDNA, TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, 
CA), and target gene assay mix containing sequence-specific primers and 6-
carboxyfluorescein (6-FAM) dye–labeled TaqMan minor groove binder (MGB) probe 
(Applied Biosystems). Amplification with 18S endogenous control assay mix was used 
for controls. PCR was carried out in triplicate for each sample. Data quantitation was 
performed using the relative standard curve method. Expression levels of the genes were 
normalized by 18S mRNA. To detect expression of cytokines IL-6, TGF-!, IL-12, IL-10, 
PCR was performed with 12.5 µl SYBR Master Mixture (Applied Biosystems, Foster 
City, CA, USA), and the following primers: (sense+): IL-6: 5’-
ATCCAGTTGCCTTCTTGGGACTGA-3’; IL-12: 5’-
ATGCAGCAAGTGGGCATGTGTT -3’; TGF-!: 5’-
TACGTCAGACATTCCGGGAAGCAGT-3’; IL-10: 5’-
TACCAAAGCCACAAAGCAGCCT-3’. The expression of IL-6, TGF-!, IL-12, and IL-
10 were normalized to !-actin. (5‘-ACCGCTCGTTGCCAATAGTGATGA-3’) 
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Western blotting.  
Cells were lysed in TNE buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA) containing 1% NP40 in the presence of protease and phosphatase inhibitors. 
Isolation of membrane and cytoplasmic compartments was achieved using Qproteome 
Cell Compartment Kit (Qiagen Inc., Valencia, CA) according to manufacturer’s 
instructions. Protein lysates were subjected to 8% SDS-PAGE and transferred to PVDF 
membranes. Membranes were probed with appropriate primary Abs overnight at 4°C. 
Membranes were washed and incubated overnight at 4°C with secondary Ab conjugated 
with peroxidase. Results were visualized by chemiluminescence detection using a 
commercial kit (Amersham Biosciences). To confirm equal loading, membranes were 
stripped and reprobed with antibody against !-actin (Santa Cruz Biotechonology, Santa 
Cruz, CA) 
 
Evaluation of T cell function.  
Proliferation. Splenocytes from either 2C transgenic mice or OT-1 mice, depleted 
of red cells, were placed in triplicates into U-bottom 96-well plate (1 x 105/well). For 
antigen-specific responses, splenocytes were cultured in the presence of cognate antigen 
(2C-specific peptide SIYRYYGL or OT-1 specific peptide SIINFEKL) and cultured for a 
total of 72 hr. For anti-CD3/CD28 antibody-induced T cell proliferation, splenocytes 
were cultured in the presence of 1 µg/ml anti-CD3 Ab and 5 µg/ml anti-CD28 Ab. 
Eighteen hours before harvesting, cells were pulsed with 3H-thymidine (1 µCi/well; 
Amersham Biosciences). 3H-Thymidine uptake was counted using a liquid scintillation 
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counter and expressed as counts per minute (CPM). IFN-! production. The number of 
IFN-!-producing cells in response to cognate antigens or CD3/CD28 antibodies was 
evaluated in ELISPOT assay as described (10). Each well contained 1 x 105 splenocytes. 
The number of spots was counted in triplicates and calculated by an automatic ELISPOT 
counter (Cellular Technology).  
 
EMSA.  
Nuclear extracts were prepared in hypertonic buffer containing 20 mM HEPES 
(pH 7.9), 420 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20% glycerol, 1 mM DTT, and 
protease and phosphatase inhibitors cocktail. Extracts were normalized for total protein, 
and 5 µg of protein was incubated with 32P-labeled probes containing: STAT1 and 
STAT3 sequence, 5’-AGCTTCATTTCCCAGAAATCCCTA-3’; p47phox sequence, 5’-
AGCTTCATTTCCCAGATATCCCTA-3’; or mutant sequence, 5’-
AGCTTCATTGCACTCATATCCCTA-3’. Protein-DNA complexes were resolved by 
nondenaturing PAGE and detected by autoradiography.  
 
Chromatin Immunoprecipitation (ChIP) assay.  
32D cells were cultured in 10% FBS RPMI 1640, supplemented with IL-3. 
Preparation of chromatin-DNA and ChIP assay were performed using a kit from Upstate 
Biotechnology (Lake Placid, NY), anti-STAT3 antibody from Cell Signaling 
Technology, normal rabbit IgG from Santa Cruz Biotechnology, protein A 
agarose/salmon sperm DNA from Upstate (Millipore, Billerica, MA). Sonication was 
performed using Branson Sonifier (model 450, VWR Scientific, West Chester, PA). After 
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reversal of crosslinking, purified DNA was subjected to PCR with the following primers 
spanning the potential STAT3 binding site in the p47phox promoter: 5’-
AGTTAAAGGCATGTGCCACCACTG -3’, and 5’-
TACACCTGCGTGCAGACATCATCT-3’.  
Primers for !-actin: 5’-TAGGGTGTAGACTCTTTGCAGCCA-3’, and 5’-
AGCGTCTGGTTCCCAATACTGTGT-3’.  
 
Experiments with embryonic stem (ES) cells.  
R1 ES cells were transfected with empty RcCMV-Neo vector (R1-C) or STAT3c 
plasmid (R1-Stat3C)(18) using lipofectamin. ES transfectants were selected in DMEM 
containing G418 (0.2 mg/mL), 15% ES cell certified FBS (Gibco, Rockville, MD), 
eukocyte inhibitory factor (LIF; 1000 U, Chemocon, Temecula, CA), 0.1 mM 
nonessential amino acid, 100 µM 2-mecaptoethenol, and 2 mM L-glutamine.  
 
Statistics.  
Statistical analysis was performed using non parametric Mann-Whitney test and 
GraphPad Prism software (La Jolla, CA). In all cases p values were calculated using two-
sided t test. 
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RESULTS 
 
I. Suppressive Mechanism of MDSC in Peripheral Lymphoid Organs: Role of 
NADPH Oxidase (NOX2) and Signal Transducer and Activator of Transcription 3 
(STAT3) 
ROS molecules have been implicated in the attenuation of T-cell immune 
responses by MDSC (52,54,56). Treatment of MDSCs with ROS inhibitors (catalase and 
uric acid) abrogated antigen-specific inhibition of CD8+ T-cells by splenic MDSC (18). 
Neutralization of ROS with the H2O2 scavenger catalase improved the ability of MDSC 
to differentiate to mature myeloid cells in vitro (127). These studies established critical 
role of ROS in MDSC function. We thus intended to identify the source of ROS in 
MDSC and the mechanism leading to its production. To this end we analyzed the 
expression of the subunits of the NOX2 complex and its possible regulation by STAT3, 
whose enhanced activity had been previously demonstrated in MDSC (51).  
 
Hyper-production of ROS in splenic MDSC from tumor-bearing mice  
We first addressed the question whether up-regulation of ROS in splenic MDSC was a 
wide-spread phenomenon observed in several different tumor models, since prior studies 
demonstrating increased ROS generation by MDSC were carried using a select number of 
models. We tested seven mouse tumor models of sarcomas, thymoma, colon, mammary, 
and lung carcinomas on BALB/c and C57BL/6 strains. A different number of tumor cells 
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were injected s.c. in order to allow for the development of similar size tumors (1.5 cm in 
diameter) within 3 weeks after tumor inoculation. This time frame was selected as it is 
widely used in most studies of tumor-associated immune suppression. Splenocytes were 
isolated, stimulated with PMA and labeled with anti-Gr-1 and anti-CD11b antibodies to 
identify MDSC in tumor-bearing mice or immature myeloid cells (IMC) in naïve tumor-
free mice. ROS levels were measured using the oxidation-sensitive fluorescent dye 
DCFDA within the population of Gr-1+CD11b+ MDSC or IMC. MDSC from all tumor 
models without exception demonstrated a significantly higher level of ROS than their 
control counterparts (Fig. 1A). To verify those observations using a different 
experimental system, we measured the level of hydrogen peroxide (H2O2) in MDSC 
isolated from spleens of CT26 and EL4 tumor-bearing mice. In both tumor models, 
MDSC produced substantially higher level of H2O2 than IMC (Fig. 1B). Higher level ( p 
< 0.05) of ROS production by MDSC was also detected in response to other stimuli 
(ionomycin and LPS) indicating that this effect is not restricted to PMA (Fig. 1C). 
Furthermore, ROS levels were measured in MDSC during dynamic tumor growth. The 
significant increase of ROS levels in MDSC became most prominent 3 weeks after tumor 
inoculation (Fig. 1D) which coincides with substantial expansion of MDSC (unpublished 
observations) in these models.  
 
ROS generation by MDSC in peripheral blood samples of head and neck cancer 
patients  
To extend our studies to the clinic, we evaluated ROS levels in MDSC from 
patients with stage III head and neck cancer (HNC). In humans, MDSC are identifiable as 
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CD11b+ CD14– CD33+ cells and previous studies have shown that these cells have 
functional characteristics of MDSC (128,129). Peripheral blood mononuclear cells from 
healthy volunteers and patients were labeled with APC-conjugated anti-CD11b, PerCp-
Cy5.5-conjugated CD14 and PE-Cy7-conjugated anti-CD33 antibodies and loaded with 
DCFDA. ROS levels were evaluated within the population of CD11b+ CD14– CD33+ 
cells. MDSC in peripheral blood from patients demonstrated an approximately five-fold 
higher level of ROS upregulation following PMA-stimulation compared to cells with the 
same phenotype from healthy volunteers (p=0.0165) (Fig. 2).  
 
Increased transcription of NAPDH Oxidase controls ROS upregulation and 
suppressive activity of peripheral MDSC. 
Though ROS can be produced in cells by several different mechanisms, the 
primary source of ROS in leukocytes is by NADPH oxidase (NOX2). The oxidase is a 
multicomponent enzyme consisting of two membrane proteins, gp91phox and p22phox and 
at least four cytosolic components: p47phox, p67phox, p40phox and a small G protein Rac 
(58). We measured expression of these subunits in MDSC isolated from naïve tumor-free 
and CT-26 tumor-bearing BALB/c mice using qRT-PCR. MDSC from tumor-bearing 
mice had a substantially higher level of mRNA for several major NOX2 components. 
However, the most prominent increase was observed in the level of expression of 
gp91phox and p47phox (Fig. 3A). Increased expression of these genes was also observed in 
two other tested tumor models (EL-4 and MC38) (Fig. 3B). The most significant increase 
in gp91phox and p47phox expression was detected in mice 3 weeks after tumor inoculation, 
which coincided with the time when the most elevated level of ROS was observed in 
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these cells (Fig. 1D). In accordance with our PCR results, MDSC from tumor-bearing 
mice had substantially higher level of p47phox and gp91phox proteins in whole cell lysates 
than IMCs from naïve mice (Fig. 3C).  Up-regulation of these proteins was also seen in 
the membrane fraction of MDSC from tumor-bearing mice (Fig. 3D), which is possibly 
indicative of an elevated activation status when compared to naive counterparts. 
To investigate a direct contribution of NOX2 to the hyper-production of ROS we 
used mice lacking gp91phox. These mice are used to study chronic granulomatous disease 
(CGD), a recessive disorder characterized by a defective phagocyte respiratory burst 
oxidase, life-threatening pyogenic infections and inflammatory granulomas (130). Gene 
targeting was used to generate mice with a null allele of the 91 kD subunit of NADPH 
Oxidase. The affected mice lack phagocyte O2- production, and manifest increased 
susceptibility to bacterial and fungal infections. EL-4 tumor was established in wild-type 
and gp91phox-deficient mice and the level of ROS was measured in MDSC 3 weeks after 
tumor inoculation. In contrast to their wild-type counterparts, gp91phox-deficient MDSC 
from tumor-bearing mice showed no increase in the level of ROS when compared to 
MDSC from tumor-free mice (Fig. 4A); it’s also important to note that gp91phox-/- mice 
smaller tumor growth compared to wild-type mice, though the differences were not 
statistically significant (data not shown). We then asked whether lack of NOX2 activity 
affected suppressive activity of MDSC as well as their inability to differentiate. Gr-
1+CD11b+ cells were isolated from spleens of naïve tumor-free mice, spleens of wild-type 
EL-4 tumor-bearing mice and gp91phox-/- EL-4 tumor-bearing mice and their ability to 
inhibit T-cell responses was compared. MDSC from tumor-bearing mice induced 
significant suppression of IFN-! production and proliferation of antigen-specific CD8+T 
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cells in response to stimulation with a specific peptide (Fig. 4B,C). In striking contrast 
MDSC from NOX2 deficient mice failed to suppress T-cell function (Fig. 4B,C). To 
evaluate the effect of NOX2 on MDSC differentiation, Gr-1+CD11b+ cells isolated from 
wild-type and gp91phox-/- tumor-bearing mice were cultured in vitro for 5 days with GM-
CSF in the presence of tumor-cell-conditioned medium (TCCM). Almost 40% of MDSC 
from wild-type mice retained the immature phenotype (Gr-1+CD11b+), with a small 
proportion of cells differentiating to either DCs or macrophages. In contrast, the majority 
of MDSC from gp91phox-/- tumor-bearing mice differentiated to F4/80+Gr-1- macrophages 
or CD11c+CD11b+ DCs (Fig. 4D).  
 
STAT3 recognizes promoter of NADPH Oxidase subunit. 
The STAT3 transcription factor plays a critical role in accumulation of MDSC in 
tumor-bearing mice (51, 131); this led us to hypothesize that STAT3 could be involved in 
the increased NOX2 levels in MDSC. To assess the role of STAT3 in regulation of 
NOX2 we concentrated on one subunit - p47phox. To determine whether STAT3 could 
bind the p47phox promoter, a chromatin immunoprecipitation (ChIP) assay was performed 
with the 32D myeloid cell line. 32D cells are murine myeloid cells that depend on IL-3 
for growth and rapidly undergo apoptosis after IL-3 withdrawal (132). Due to the 
requirement for IL-3, these cells constantly have high levels of STAT3 phosphorylation 
(133), making them a perfect candidate for this experiment As shown in Fig. 5A, anti-
STAT3 antibody precipitated DNA that was amplified by primers specific for the p47phox 
promoter region, indicating STAT3 binding to the p47phox promoter. The promoter region 
of this gene contains the sequence TTCCCAGAG, which is almost identical to the 
 35 
STAT3 binding sequence TTCCCAGAA with the exception of one nucleotide. To verify 
that these two sequences had similar binding pattern, embryonic stem (ES) cells were 
transfected with a constitutively active STAT3 mutant (STAT3C) (131). Nuclear extract 
was prepared and binding of probes containing the consensus STAT3 binding sequence 
and p47phox promoter-derived sequence was assessed by EMSA. Both probes showed the 
same pattern of binding. Importantly, binding of the p47phox-derived probe was 
completely blocked by non-labeled probe containing the STAT3 consensus sequence 
(Fig. 5B).   
 
Stat3 activity regulates expression of NADPH Oxidase  
To investigate the requirement of STAT3 for ROS production and p47phox 
expression in MDSC, we used mice with a targeted disruption of STAT3 in myeloid cells 
STAT3 mutant mice (STAT3MT) were generated as described previously (134). Briefly, 
mice in which the STAT3 gene is flanked by two loxP sites were crossed to a mouse in 
which the cre cDNA is inserted into the mouse lysozyme M gene by a knockin approach. 
Lysozyme M is exclusively expressed in cells of the monocyte/macrophage and 
granulocyte lineages of hematopoietic differentiation; disruption of the STAT3 gene was 
therefore expected to take place only in these cell types. The ensuing STAT3 mutant 
protein lacks amino acids 701-732, including the tyrosine and serine residues critical for 
STAT activation.  
EL-4 tumors were established in STAT3MT or their wild-type littermates (WT). 
Since lack of STAT3 prevented the development of MDSC (51 and data not shown) we 
evaluated the effect of STAT3 disruption of NOX2 in CD11b+ macrophages. Peritoneal 
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macrophages were induced by injection of thioglycollate and collected 3 days post-
treatment. Cells were labeled with anti-CD11b antibody and their ability to generate ROS 
was analyzed. Both spontaneous and PMA-inducible levels of ROS in STAT3MT CD11b+ 
cells were substantially lower than that in their wild-type counterparts (Fig. 6A). CD11b+ 
macrophages were isolated from the peritoneum of tumor-free and tumor-bearing WT or 
STAT3MT mice and the expression of gp91phox and p47phox evaluated by qRT-PCR. 
Disruption of STAT3 resulted in significant reduction in the expression of gp91phox and 
p47phox gene (Fig. 6B) and p47phox protein (Fig. 6C). We then assessed the effect of over-
expression of STAT3 on NOX2 by analyzing NOX2 mRNA in STAT3C-transfected ES 
cells (135). Normally, ES cells cultured in the presence of leukemia inhibitory factor 
(LIF) display functionally active phospho-STAT3. LIF withdrawal leads to a substantial 
decrease in pY705STAT3 within 48 hr (40). Over-expression of STAT3C in ES cells 
prevented downregulation of pY-STAT3 and resulted in a substantial increase in the 
expression of gp91phox and p47phox (Fig. 6D). Taken together, these data indicate that 
STAT3 directly regulates NOX2 expression and ROS production in myeloid cells.  
Additionally, we used the STAT3 inhibitor JSI-124 (25) to block STAT3 activity 
in MDSC in vitro and compare its effects on ROS generation. JSI-124 is a plant natural 
product identified previously as cucurbitacin I, a member of the cucurbitacin family of 
compounds that are isolated from various plant families such as the Cucurbitaceae and 
Cruciferae and have been used as folk medicines for centuries in countries such as China 
and India. JSI-124 reduced the levels of phosphotyrosine STAT3 and tyrosine 
phosphorylation of its upstream activator JAK2 without affecting total protein levels in 
many human cancer cell lines including pancreatic, lung, and breast carcinomasand. The 
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high selectivity of JSI-124 for disrupting STAT3 signaling is demonstrated by the fact 
that in human tumor cell lines, neither the PI3k/Akt, Ras/Raf/MEK/ERK, or the JNK 
signaling pathways are affected by JSI (Blaskovich 2003). Our lab independently showed 
that JSI-124 down-regulates STAT3 phosphorylation in MDSC without affecting 
phosphorylation of other STAT family members. Treatment of tumor-bearing mice with 
JSI-124 reduced the presence in of MDSC in spleens (137). MDSC were isolated from 
spleens of 3-week MC38 tumor-bearing mice and treated with JSI-124 in the presence of 
TCCM. Twenty-four hour treatment with the STAT3 inhibitor dramatically reduced the 
level of ROS in these cells (Fig 7A). JSI-124 caused a decrease in the expression of 
p47phox and gp91phox as early as 6 hr after the start of treatment (Fig. 7B). JSI-124 
treatment also resulted in a substantial decrease in the level of p47phox protein in these 
cells (Fig. 7C).  
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Figure 1. ROS level in MDSC from tumor-bearing mice and cancer patients  
A. Spleens from naïve tumor-free and tumor-bearing mice were collected 3 weeks after tumor 
injection. Splenocytes were stimulated with PMA and labeled anti-Gr-1 antibody and anti-CD11b 
Abs. ROS were measured in Gr-1+CD11b+ cells by labeling cells with the oxidation-sensitive dye 
DCFDA as described in Materials & Methods. Each group included 4 mice. Avg. and std. dev. of 
the mean fluorescence intensity (MFI) are shown. B. H2O2
 
production by spleen MDSC from CT-
26 or EL-4 tumor-bearing mice. H2O2
 
was measured as described in Materials & Methods. C. 
Splenocytes from EL-4 tumor-bearing and naive C57BL/6 mice were loaded with 2 mM DCFDA 
and cultured at 37°C for 30 min in RPMI 1640 in the presence of either ionomycin (2 µM) or 
LPS (1 µg/ml). ROS level was measured within the population of Gr-1+CD11b+ cells. D. ROS 
generation by MDSC from spleens of CT26, EL-4, and MC38 tumor-bearing mice were 
evaluated at different time points after tumor injection.  
 
 
 
D. 
B. 
C. 
A. 
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Figure 2. ROS production in MDSC from patients with head and neck cancer.  
Peripheral blood MNC from healthy donors and patients with HNC were labeled with a cocktail 
of anti-CD11b, anti-CD14 and anti-CD33-specific antibodies and stained with DCFDA to detect 
ROS level within the population of CD11b+CD14-CD33+
 
cells. A. The gating strategy to identify 
MDSC. CD14-CD11b+
 
cells were gated first followed by gating of CD33+
 
cells. Histograms show 
representative fluorescence intensities of DCFDA in CD14-CD11b+CD33+
 
MDSC from patients 
and donors before and after PMA stimulation. B. Summarized data obtained from 5 patients and 5 
healthy donors. *-statistically significant difference (p<0.05)  
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Figure 3. Up-regulation of NADPH Oxidase in MDSC  
A. Gr-1+ cells were isolated from spleens of naïve or CT-26 tumor-bearing mice. RNA was 
extracted and expression of NADPH oxidase subunits was measured in triplicates by qRT-PCR. 
Three experiments with the same results were performed. *-statistically significant difference 
(p<0.05) between control and tumor-bearing mice. B. MDSC from spleens of CT26, EL-4, and 
MC38 tumor-bearing mice were evaluated at different time points after tumor injection. Gr-
1+CD11b+ cells were isolated on weeks 2 and 3 after injection of tumor cells and the expression of 
gp91phox and p47phox was measured by qRT-PCR. Each experiment was performed in triplicates 
and each group included 3 mice. C,D. Protein levels of gp91phox and p47phox were determined in 
total cell lysate (C) or membrane fractions (D) of Gr-1+CD11b+ isolated cells indicative of an 
elevated activation status when compared to naive counterparts. 
 
 
 
 
A 
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Figure 4. NADPH Oxidase is responsible for ROS production in splenic MDSC and the 
antigen-specific suppression of T cells.  
A. Production of ROS was evaluated in splenic Gr-1+CD11b+ MDSC from EL-4 tumor-bearing 
and gp91phox
 
knockout mice. Each group included 5 mice. *-statistically significant difference 
(p<0.05) between wild-type and gp91phox-/-
 
tumor-bearing mice. B, C. MDSC were isolated from 
naïve, wild-type, or gp91
 
KO mice and cultured with 1x105 splenocytes from OT-1 transgenic 
mice. IFN-! production was measured in triplicates in ELISPOT assay (B). (C) Proliferation after 
stimulation with OVA-derived specific or control peptide (10 µg/ml) was determined. CPM – 
counts per minutes. Thymidine uptake in cells stimulated with control peptide was <1000 cpm. 
The values obtained from cells stimulated with control peptides were subtracted from values from 
cells stimulated with specific peptide. D. Splenic MDSC from wild-type and gp91 KO tumor-
bearing mice and cultured with 20 ng/ml GM-CSF and 25% v/v TCCM for 5 days. Cell 
phenotype was evaluated by flow cytometry. Cumulative results from three performed 
experiments are shown. 
 
 
A 
 
B 
 
C 
D 
 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. STAT3 recognition of NADPH Oxidase subunit promoter . 
A, B. Nuclear extracts from STAT3C-transfected ES cells were prepared and used in EMSA. SIE 
–conventional STAT3 specific probe, p47phox sequence derived from promoter region of p47phox. 
Mutant probe – mutant p47phox derived probe, SIE cold inhibition – binding to p47phox derived 
probe in the presence of 50-fold excess of unlabeled SIE probe. B. ChIP assay. DNA from 32D 
cells was precipitated with either anti-STAT3 antibody (STAT3) or control rabbit IgG (IgG). 
PCR was performed with primers specific for promoter regions of p47phox
 
or !-actin genes (C). 
Input – PCR reaction performed with DNA isolated from nuclear extract without precipitation.  
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Figure 6. STAT3 regulates expression of NADPH oxidase  
A, B, C. EL-4 tumor cells were injected into wild-type (WT) or STAT3-mutant (STAT3MT) mice. 
Cells from the peritoneum were flushed out and collected 21 days after injection of EL-4 cells. To 
recruit macrophages, thioglycollate was injected i.p. 3 days prior to sacrificing animals. 
Peritoneal cells were stained with anti-CD11b antibody and production of ROS was analyzed (A). 
CD11b+ macrophages were isolated from peritoneum of WT or STAT3MT mice. The expression 
of p47phox was assessed by Real-Time PCR (B) and amount of p47phox protein was determined by 
Western blotting (C). D. R1-ES cells were transfected with either control plasmid (R1-C) or 
Stat3C plasmid (R1-Stat3C) (18). Expression of gp91phox and p47phox after transfection was 
determined.  
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Figure 7. Effect of STAT3 inhibitor JSI-124 on ROS level in MDSC  
Gr-1+ cells were isolated from spleens of 3-week MC38 tumor-bearing mice. Cells were cultured 
with tumor-cell-conditioned medium for 24 hours and treated with the STAT3 inhibitor, JSI-124 
(1.5 µM). A. ROS level measured in Gr-1+CD11b+ cells. B. Expression of gp91phox
 
and p47phox at 
different time points after treatment with JSI-124. C. Levels of p47phox protein in JSI-124 treated 
Gr-1+CD11b+cells were analyzed by Western blotting. Hela cells were used as positive controls 
for phosphorylated STAT3 
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II. Suppressive Activity and Differentiation of MDSC in the Tumor Site: the Role of 
Tumor Hypoxia and HIF-1a.  
MDSC have been reported to inhibit T cell activation by manipulating l-arginine 
metabolism. The action of the enzymes Arg1 and iNOS, independently or synergistically, 
has been reported to inhibit the response of T lymphocytes to antigen. Although 
simultaneous activation of both enzymes has been argued to be unfeasible because 
activation of one would limit the availability of l-arginine as a substrate for the other, if 
we take kinetics into consideration we find that the enzymatic activity of either enzyme 
should be greatly affected (138). In fact, the combined activity of ARG and NOS is 
important for the suppressive activity of tumor-infiltrating CD11b+ myeloid cells (78) 
and of Gr-1+CD11b+ cells isolated from the spleen of mice that are chronically infected 
with helminthes (140).  
Interestingly, despite large number of MDSC in spleens and lymph nodes of 
tumor-bearing mice, and in the peripheral blood of cancer patients with advanced disease, 
T cells in these compartments seem to retain the ability to respond to different tumor non-
specific stimuli including viruses, lectins, IL-2, and stimulation with CD3- and CD28-
specific antibodies (140-143). In a sharp contrast, T cells directly isolated from tumors 
display profound defects in their ability to respond to those stimuli (144-146), suggesting 
that T cells in the lymphoid organs and in tumor tissues are inhibited by distinct 
mechanisms. Based on these observations, we hypothesized that MDSC inside tumor 
tissues exploited a suppressive mechanism different that MDSC in peripheral lymphoid 
organs. The roles of hypoxia, a prominent feature of tumor tissues, and the transcription 
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factor HIF-1! were also evaluated in controlling MDSC activity. We expanded our 
studies to the differentiation of MDSC inside the tumor microenvironment and the 
possible regulatory role of this phenomenon by hypoxia and HIF-1!. 
 
Phenotype of MDSC in the tumor site 
In order to compare MDSC from the tumor site to MDSC from peripheral 
lymphoid organs (spleen), we developed a model where EL-4 tumor grows as an ascitis 
in C57BL/6 mice. The dose of EL-4 cells was selected to form an ascitis within 3 weeks 
after tumor injection. MDSC were sorted based on Gr-1 and CD11b co-expression from 
the spleen and tumor of the same mouse (Fig. 8A).  
MDSC from both sites expressed the same level of Gr-1 and CD11b molecules 
and had similar mixed granulocytic and monocytic cell morphology (Fig. 8B). The 
number of total MDSC in the ascitis of our model was on average 3-4 fold lower than in 
spleen. Recent studies have determined that MDSC consists of two major subsets: cells 
with granulocytic phenotype (CD11b+Ly6G+Ly6Clow) and cells with monocytic 
phenotype (CD11b+Ly6G-Ly6Chigh) (20,147). We decided to analyze the morphology of 
MDSC from both sites to compare possible differences in MDSC composition. We found 
that granulocytic MDSC were the predominant type of MDSC in both sites. Moreover, 
the ratio of granulocytic and monocytic MDSC isolated from tumor or spleens was 
practically identical (Fig. 8C). The CD11c marker specific for DCs was not expressed on 
either spleen or tumor MDSC and almost all cells from both sites expressed the Neu 
marker (Fig. 8C). A slightly higher proportion of Gr-1+CD11b+ MDSC from the tumor 
site did exhibit low expression of the macrophage marker F4/80 than did MDSC from 
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spleens (p=0.06) (Fig. 8C). Thus, MDSC from the tumor and spleen of tumor-bearing 
mice had similar morphology and phenotype.  
 
Function of MDSC in the tumor microenvironment. 
We proceeded to compare the ability of tumor and spleen MDSC to suppress 
antigen-specific T cell activation. Again, we evaluated two basic functions of T cells: 
IFN-! production and T-cell proliferation. The antigen-specific response to MHC class I-
restricted SIYRYYGL (SIY) peptide was measured in 2C transgenic CD8+ T cells. 
MDSC were isolated from the tumor site and spleens of the same mice and used under 
the same experimental conditions; Gr-1+CD11b+ immature myeloid cells (IMC) from 
spleens of naïve tumor-free mice were used as a control. As was demonstrated in 
previous studies, IMC lack immunosuppressive activity (53,78,148,149) In contrast, both 
spleen and tumor MDSC effectively suppressed the antigen-specific T-cell response, 
though the level of suppression was significantly (p<0.05) higher in tumor MDSC (Fig. 
9A). We also evaluated the T cell response after activation with anti-CD3/CD28 
antibodies. Under this scenario, spleen MDSC did not suppress the T-cell response, 
whereas tumor MDSC exerted a profound suppressive effect (Fig. 9B). 
 A similar effect was observed in a spontaneous lung cancer model. The 
mCC10TAg transgene was made by fusing the coding sequences of the SV40 TAg 
oncogene with the mCC10 promoter (150), a promoter that targets expression of the 
transgene only to proximal pulmonary lung epithelial cells. Under this model, mice 
develop multifocal pulmonary adenocarcinoma in the lung at three months of age. MDSC 
were isolated from tumor or spleens of the three-month-old mice and then added to 
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responder cells from naïve mice stimulated with anti-CD3/CD28 antibodies. Tumor 
MDSC showed a marked suppressive activity, whereas spleen MDSC failed to suppress 
non-specific T-cell proliferation (Fig. 9C). Thus, MDSC from the tumor site and spleen 
of the same mouse exhibit a marked difference in their ability to suppress T-cell function.  
 
Manipulation of L-arginine metabolism as the suppressive mechanism employed by 
Tumor-MDSC 
Although recently MDSC have been attributed with multiple novel suppressive 
methods, the traditional factors implicated in MDSC-mediated immunosuppression 
consisted of ROS and manipulation of l-arginine (151,152). We first evaluated ROS 
levels within the population of MDSC from spleen and tumors. IMC from spleen of naïve 
mice served as controls. As shown in the previous section, MDSC from spleens of tumor-
bearing mice displayed a significantly higher level of ROS than the cells from tumor-free 
mice. Surprisingly, ROS production in tumor MDSC was significantly lower than that of 
splenic MDSC (Fig. 10A). Expression of gp91phox and p47phox components of NOX2 were 
also significantly lower in MDSC isolated from the tumor site than that in MDSC from 
the spleen (Fig. 10B). In contrast, MDSC isolated from the tumor site displayed lofty 
arginase activity and high expression of arg1 than spleen MDSC from the same mice 
(Fig. 10C). In addition, large amounts of NO were detected in cultures of  MDSC and 
splenocytes. The expression of iNOS was >10-fold higher in MDSC from the tumor site 
after stimulation with IFN-y (Fig. 10D).  
To determine if ROS played any role in the suppressive activity of tumor MDSC, 
we performed experiments with gp91phox-/- tumor-bearing mice. Lack of ROS eliminated 
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inhibitory potential of spleen MDSC but the suppressive potential of tumor MDSC was 
not affected (Fig. 10E). In the other hand, inhibition of iNOS with LMMA, and arg1 with 
nor-NOHA, completely abrogated suppressive activity of tumor-derived MDSC (Fig. 
10F). From these experiments we concluded that MDSC from the tumor use arginase and 
NO to suppress T-cell function, whereas splenic MDSC primarily utilize the ROS-
mediated mechanism. 
 
MDSC in Tumor Tissues of Cancer Patients. 
Our data indicated that MDSC from the tumor site and peripheral lymphoid 
organs of tumor-bearing mice differed in their ability to produce ROS and NO. To test 
whether a similar phenomenon is observed in cancer patients, we studied paired samples 
of peripheral blood and tumor tissues obtained from patients with head and neck cancer. 
MDSC were defined as CD14-CD11b+CD33+ cells (Fig. 11A). ROS and inos were 
measured in MDSC using flow cytometry. MDSC in the tumor had significantly lower 
ROS production than MDSC in peripheral blood (Fig. 11B). In contrast, inos levels in 
tumor MDSC were substantially higher than in blood MDSC (Fig. 11C). Thus, these 
results, which are similar to those observed in tumor-bearing mice, suggest that 
differences in MDSC may represent general phenomenon. 
 
Effect of tumor microenvironment on MDSC function and differentiation 
MDSC are a heterogeneous group of cells. Therefore, despite similarities in the 
morphology and phenotype of MDSC isolated from tumor sites and spleens, it was 
difficult for us to formally exclude the possibility that MDSC in different sites may 
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represent different populations of myeloid cells (i.e. TAMs). To address this question as 
well as to identify the mechanisms of MDSC function in the tumor site, we performed a 
direct transfer of Gr-1+CD11b+ MDSC isolated from spleens of EL-4 tumor-bearing 
congenic (CD45.1+) mice into the ascitis of EL-4 tumor-bearing C57BL/6 (CD45.2+) 
recipients. EL-4 cells, a lymphoma cell lime, express CD45.2 but not the CD45.1 marker 
(data not shown). This system allowed for discrimination between tumor cells and 
MDSC. In parallel, MDSC were injected i.v. into either EL-4 tumor-bearing or tumor-
free recipients to evaluate donor cells in the spleen. Donor cells isolated from spleens 4 hr 
after the transfer retained their significant (p<0.01) ability to suppress antigen-specific T-
cell responses (Fig. 12A). However, these cells failed to inhibit the T cell response to a-
CD3/CD28 stimulation (Fig. 12B). In contrast, donor cells isolated from tumor site 4 hr 
after the transfer exhibited strong suppressive activity of both antigen-specific and non-
antigenic T cell response (Fig. 12A,B). The expression of arg1 and inos in donor cells 
isolated from tumors was significantly higher; simultaneously p47phox mRNA was 
significantly lower than donor cells in spleens (Fig. 12C). At  longer time points, 18 hr 
after post transfer to be specific, donor cells isolated from tumor sites gained dramatic 
suppressive activity (Fig. 12D) , their expression levels of arg1 and inos elevated (Fig. 
12E), and their ability to generate ROS was diminished (Fig. 12F). Thus, substantial 
changes in MDSC suppressive activity and up-regulation of inos and arg1 were observed 
as early as 4 hr after adoptive transfer of MDSC into the tumor site. 
It is known that MDSC can differentiate into mature myeloid cells. We therefore 
investigated the fate of these cells after transfer into the tumor site and donor cells that 
reached the spleen. CD45.1+ MDSC isolated from spleens of tumor-bearing mice were 
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transferred i.v. or injected directly into ascitis of CD45.2+ recipients. No differences were 
observed in the phenotype of cells isolated 4 hr after the transfer (data not shown). 
Eighteen hour post transfer most of the donor MDSC (>70%) in the spleen and tumor site 
still retained the MDSC phenotype (Gr-1+CD11b+) (Fig. 13A). Donor cells that lost Gr-1 
expression were represented in the spleens primarily as CD11c+ DCs, whereas in the 
tumor site as F4/80+ macrophages. After 48 hr, the proportion of Gr-1+CD11b+ MDSC 
among donor cells in spleens remained about the same (> 60%). However, in the tumor 
site it was substantially decreased with less than 30% of donor cells retaining the 
phenotype of MDSC (Fig. 13B). Practically all Gr-1 negative donor cells in the tumor 
site, but only less than 30% of cells in the spleen, were F4/80+CD11b+ macrophages. In 
contrast, few Gr-1- cells in the tumor site express the CD11c marker of DCs, whereas in 
spleen more than 30% of these cells were CD11c+ (Fig. 13B). Three days after the 
transfer, all Gr-1 negative donor cells in the tumor site remained F4/80+CD11b+ 
macrophages, whereas macrophages represented less than 20% of these cells in spleen 
(Fig. 13C). No CD11c+ donor cells were detectable in spleens, which may reflect the 
possible migration of DCs out of the spleen. Thus, in the tumor microenvironment, 
MDSC rapidly differentiated into F4/80+CD11b+ TAM. In contrast, MDSC in spleens 
remained undifferentiated much longer and differentiated equally to macrophages and 
DCs. 
 
Effect of Hypoxia in MDSC function and differentiation. 
Our data demonstrates that the tumor microenvironment rapidly changes the 
function of MDSC and promotes their differentiation to TAM. We investigated the 
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possible mechanism of this effect. Hypoxia is one of the major characteristics of the 
tumor microenvironment and we decided to test the effect of hypoxia on MDSC. We 
incubated MDSC isolated from spleens of tumor-bearing mice in complete culture 
medium and GM-CSF at normoxic or hypoxic (1% O2) conditions for 48 hr. Hypoxia 
significantly (p<0.05) reduced the expression of gp91phox and p47phox components of 
NOX2 (Fig. 14A), which resulted in a substantial decrease in the level of ROS production 
in these cells (Fig. 14B). In contrast, MDSC subjugated to hypoxia had elevated 
expression of arg1 and inos (Fig. 14C). MDSC cultured in hypoxia acquired the ability to 
suppress T-cell activation in response to anti-CD3/CD28 antibody (Fig. 14D). Thus, 
hypoxia recapitulated the effect of the tumor microenvironment on MDSC function. 
To assess the effect of hypoxia on MDSC differentiation, Gr-1+CD11b+ cells from 
spleens of tumor-bearing mice were cultured for 5 days in normoxia or hypoxia in the 
presence of GMCSF. We observed accumulation of cells with macrophage morphology 
in the hypoxic group (Fig. 15A). In hypoxia, the proportion of Gr-1+CD11b+ MDSC was 
4-fold lower compared with cells cultured at normoxia (p<0.01), whereas the proportion 
Gr-1-CD11b+F4/80+ M! was significantly higher (p<0.05) (Fig. 15B). In contrast, the 
proportion of CD11c+ cells was significantly (p<0.05) higher among the cells cultured at 
normoxia than those incubated at hypoxia (Fig. 15B). Thus, these data indicate that 
hypoxia can indeed promote the differentiation of MDSC to macrophages, similar to the 
effect observed in the tumor microenvironment. 
We then asked whether hypoxia could cause functional polarization of 
macrophages during their differentiation from MDSC. MDSC isolated from spleens of 
tumor-bearing mice were cultured at normoxia and hypoxia for 5 days, followed by 
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isolation of F4/80+ cells and evaluation of their cytokine gene expression. As controls, we 
used F4/80+ macrophages obtained from peritoneal cavities of naïve mice and F4/80+ 
cells collected from the ascitis of tumor-bearing mice.  
As expected, TAM expressed substantially higher levels of M1 markers Arg1 and 
Il-10 than control peritoneal macrophages (Fig. 15C,E). Unexpectedly, in our experiment 
TAM also expressed higher levels of M2 markers iNOS and Il-12 than control peritoneal 
M! (Fig 15D,F). The expression of TGF-! and Il-6 were very similar between the two 
groups (Fig 15G,H). Based on cytokine expression, macrophages generated from MDSC 
under hypoxic conditions very much resembled macrophages isolated directly from the 
tumor as they also expressed higher levels of Il-10, arg1, inos, Il-12, and Il-6 than 
macrophages generated under normoxic conditions. TGF-" levels were very similar in 
M! generated in vitro under either condition. These results suggest that hypoxia drives 
the differentiation of MDSC to a similar phenotype expressed by macrophages inside 
tumor tissues. The fact that in our experimental model TAM expressed cytokines 
associated with both M1 and M2 polarization states may indicate the need for revision of 
the notion that TAM are strictly M2-polarized macrophages. 
  
Requirement of HIF-1#  for tumor microenvironment- and hypoxia- induced 
changes in MDSC 
Up-regulation of HIF-1! is one of the major effects of hypoxia. We investigated 
the possible role of HIF-1! in the regulation of MDSC differentiation and function. 
Shortly after exposing splenic MDSC to hypoxia, we observed accumulation of HIF-1! 
(Fig. 16A). To test the possible role of this transcription factor on MDSC function in 
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vitro we used deferoxamine (DFO), a compound that stabilizes HIF-1!. Spleen MDSC 
from tumor-bearing mice were treated with DFO for 48 hr, washed and then added to 
splenocytes stimulated with anti-CD3/CD28 antibodies. Untreated MDSC did not 
suppress proliferation (Fig. 16B) or IFN-" production (Fig. 16C) from activated  T-cells . 
However, MDSC pre-treated with DFO caused profound suppression of T-cell function 
(Fig. 16B,C). Similar to the effects observed after treatment with hypoxia, DFO caused 
significant up-regulation of the expression of arg1, inos and a decrease in the expression 
of NOX components p47phox and gp91phox (Fig. 16D,E). It also promoted macrophage 
differentiation from MDSC during a 5-day culture with GM-CSF (Fig. 16F). Taken 
together, these results suggested that HIF-1! could be responsible for the observed effect 
of the tumor microenvironment on these cells.  
To directly address this possibility, we used mice with conditional HIF-1! 
deletion. HIF-1! flox mice were crossed with Mx-Cre mice and HIF-1! deletion was 
induced by repeated poly:IC administration (Fig. 17A). Poly:IC is a strong inducer of 
type I IFN and it could potentially affect MDSC function. Therefore, to exclude this 
possibility and to make sure that HIF-1! deletion is confined only to hematopoietic cells, 
we decided to reconstitute the bone marrow (BM) of wild-type recipients with HIF-1a 
deficient progenitors. BM cells (2x106) from CD45.2+ HIF-1!-deficient (HIF-
1!floxCre+/-) or control (HIF-1!floxCre-/-) mice were used to reconstitute lethally 
irradiated CD45.1+ congeneic naïve mice. The BM progenitors from HIF-1!-deficient 
and wild-type mice showed similar engraftment potential (Fig. 17B). We allowed two 
weeks for the myeloid compartment to repopulate in recipients. After two weeks we 
established s.c. tumors with EL-4 cells; no significant differences in tumor growth 
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between the groups were seen (data not shown). At the time of submission of this 
manuscript, generation of HIF-1a-/- animals was still ongoing. Due to the insufficient 
number of mice we cannot provide statistical significance in our results; consequently, it 
is important to disclose that the accompanying results should at this stage be regarded as 
preliminary rather than final. 
We evaluated the populations of myeloid cells 3 weeks after tumor injection (1.5 
cm in diameter). Large expansion of Gr-1+CD11b+ MDSC was observed in the spleen of 
tumor-bearing mice that received HIF-1!+/+ BM. Surprisingly, only a modest increase of 
MDSC was observed in recipients of HIF-1!-deficient BM (Fig. 17C). The proportion 
and absolute number of MDSC in the spleen of mice reconstituted with HIF-1!-deficient 
BM was significantly (p<0.01) smaller than in mice reconstituted with HIF-1!+/+ BM 
(Fig. 17C).  No significant differences were found in the proportion of macrophages and 
DCs between the tumor-bearing recipients of HIF-1!-deficient and wild-type BM cells 
(Fig. 17C). The level of ROS was evaluated within the population of spleen MDSC. The 
HIF-1!-deficient MDSC from tumor-bearing mice generated larger amounts of ROS than 
wild-type counterparts (Fig. 17D). 
To assess the effect of the tumor microenvironment on HIF-1!-deficient MDSC, 
Gr-1+CD11b+ cells were isolated from spleens of tumor-bearing mice reconstituted with 
HIF-1!-deficient or wild-type BM and then injected directly into the ascitis of CD45.1+ 
congenic mice. Twelve hours later, Gr-1+CD45.2+ donor MDSC were isolated and used 
in experiments. Similar to previous experiments, donor MDSC with wild-type HIF-1! 
showed profound suppressive activity against T cells stimulated with anti-CD3/CD28 
antibodies (Fig. 18A). The expression of arg1 and inos in donor HIF-1! positive MDSC 
 56 
was dramatically up-regulated after transfer into the tumor site (Fig. 18B). The 
suppressive effect of HIF-1!-deficient donor MDSC, as well as the expression of arg1 
and inos in these cells, was significantly (p<0.01) lower (Fig. 18A,B). The opposite effect 
was observed in the levels of ROS as HIF-1!-deficient donor MDSC had substantially 
higher ROS production than their wild-type counterparts (Fig. 18C). 
We then evaluated the differentiation of donor cells in the tumor 
microenvironment.  We gated on CD45.2+CD11b+ cells; gating of CD11b+ cells was 
necessary to exclude CD45.2 EL-4 tumor cells from the analysis. Within 12 hr after the 
transfer of either wild-type or HIF-1!-deficient MDSC, about 30% of donor 
(CD45.2+CD11b+) cells lost the expression of Gr-1 (data not shown). Most (>60%) of the 
HIF-1!-deficient Gr-1- donor cells acquired the CD11c marker, suggesting that these 
cells differentiated towards DCs, whereas CD11c was practically not expressed on wild-
type donor cells. The opposite effect was observed in the expression of F4/80 (Fig. 18D). 
The proportion of F4/80+ TAM among HIF-1!-deficient donor cells was two-fold lower 
than that among wild-type donor cells. 
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Figure 8. Phenotype of MDSC in tumor site. 
A-C. EL-4 tumor cells (3x105) were injected i.p. into C57BL/6 mice. After three weeks, spleens 
and cells from tumor ascitis were collected. Gr-1+CD11b+ MDSC were sorted (A) and their 
morphology was evaluated by staining with H&E (B) (maginification x 200). C. Analysis of 
surface markers in gated Gr-1+CD11b+ MDSC isolated from splenic and tumors of the same mice. 
Three individual experiments were performed. 
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Figure 9. Function of MDSC in tumor site.  
A,B. Gr-1+CD11b+ cells purified from spleens of tumor-free mice (naïve), or spleens (SPL) and 
ascitis (ASC) of EL-4 tumor-bearing mice were cultured at indicated ratios with 105 splenocytes 
from transgenic 2C mice. A. Splenocytes were stimulated with control and specific peptides and 
IFN-! production was measured in ELISPOT assay. Number of spots per 105 2C splenocytes is 
shown. Values in cells stimulated with control peptide were subtracted. * - statistically significant 
(p<0.05) difference from naïve mice. B. Splenocytes were stimulated with anti-CD3/CD28 
antibodies and splenocyte proliferation was evaluated using 3H-thymidine uptake. All 
experiments were performed in triplicates. A typical result of three performed experiments 
is shown. C. Splenocytes were labeled with CFSE (1µM) and cultured with MDSC 
isolated from spleens and lungs of mCC10Tg tumor-bearing mice. Splenocytes were 
stimulated with anti-CD3/CD28 antibodies and proliferation was measured by CFSE 
dilution. Three experiments with similar results were performed. 
 
 
 
 
 
 
C  
A  B  
 
 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  B 
C  
D  
E  
 60 
 
 
 
 
 
 
 
 
 
 
Figure 10. Factors regulating MDSC suppressive activity.  
A. Cells collected from the tumor site or spleens of EL-4 tumor-bearing mice were stimulated 
with PMA and labeled with 1µM DCFDA. DCFDA fluorescence was measured in Gr-1+CD11b+ 
population. Each group included 4 mice. * - statistically significant difference (p<0.05) from 
naïve mice. B. Expression of gp91phox and p47phox was measured Gr-1+CD11b+ cells isolated 
from spleens or tumor of the same mice. C. Arg 1 gene expression and enzymatic activity were 
evaluated in MDSC from tumor site and spleen. All experiments were performed in triplicates 
and repeated three times. * - statistically significant differences (p<0.05) from naïve mice; # - 
statistically significant differences between ascitis and spleen of the same mice. D. MDSC from 
spleen and tumor ascitis were stimulated with IFN-! (30 ng/mL) for 48 hr and expression of iNOS 
was measured. The same cells were mixed at the indicated ratio with 2x105 splenocytes 
stimulated with anti-CD3/CD28 antibodies. After 48 hr incubation culture medium was collected 
and assayed for nitrites. Experiments were performed in triplicates and repeated three times with 
similar results. E. Suppressive activity of MDSC from gp91phox ko mice on IFN-! production by 
transgenic 2C T cells after stimulation with either specific peptide or with anti-CD3/CD28 
antibodies. * - statistically significant differences (p<0.05) from naïve mice. F. MDSC isolated 
from spleens or tumor site were incubated at a 1:4 ratio with naive syngeneic splenocytes 
stimulated with anti-CD3/CD28 antibodies in the presence of iNOS (0.5 mM L-NNMA) and 
arginase (0.5 mM nor-NOHA) inhibitors. IFN-! production and cell proliferation were measured. 
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Figure 11. MDSC in peripheral blood and tumor tissues of cancer patients. 
Peripheral blood and tumor tissues were collected from patients with HNC during surgical 
resection. A. A typical example of gating of CD11b+CD14+CD33+ MDSC from the same patient 
in flow cytometry. B. Cells were stained with DCFDA to detect ROS level within the population 
of CD11b+CD14+CD33+ cells from the same patient. Top panel – typical example of DCFDA 
staining in these cells; bottom panel – cumulative results from six patients. ** - statistically 
significant difference between MDSC in the tumor site and peripheral blood. C. Cells were 
labeled with anti-iNOS antibody and the protein level was measured within the population of 
CD11b+CD14+CD33+ cells. Top panel – typical example of iNOS staining of one patient. Bottom 
panel – cumulative results from six patients.* - statistically significant difference between MDSC 
in the tumor site and peripheral blood. 
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Figure 12. Effect of the tumor microenvironment on MDSC function. 
MDSC isolated from spleens of congenic CD45.1+ mice bearing 3 week s.c. EL-4 tumor were 
transferred into ascitis of CD45.2+ EL-4 tumor-bearing recipients. CD45.1+ donor cells were 
recovered using magnetic beads 4 hr after cell transfer. For controls, CD45.1+ MDSC were 
transferred i.v. into EL-4 tumor-bearing recipients or naive recipients and recovered from spleens 
4 hrs after cell transfer. A. After adoptive transfer, CD45.1+ MDSC were cultured with 2C spleen 
responder cells (Resp.) (1:4 ratio) stimulated with control and specific peptides. IFN-! production 
was measured by ELISPOT assay. Each experiment was performed in triplicates and repeated 
twice. B. Similar experiments performed using stimulation with anti-CD3/CD28 antibodies. C. 
Evaluation of gene expression of argI, iNOS, and p47phox in MDSC post-adoptive transfer. Each 
experiment was performed in triplicates and repeated twice with the same results. D-F MDSC 
after 18h adoptive transfer. D. Proliferation of 2C splenocytes in the presence of MDSC 
(MDSC:splenocyte ratio 1:4) in response to stimulation with specific peptide or with anti-
CD3/CD28 antibodies. Each experiment was performed in triplicates and repeated twice. Cell 
proliferation without peptide was below 1000 CPM. E. Expression of NOX subunits, 
argI and inos. F. ROS assessment in Gr-1+CD11b+ cells before and after adoptive 
transfer. MFI for one typical experiment is shown. 
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Figure 13. Differentiation of MDSC in the tumor microenvieonment  
Phenotype of donor CD45.1+ cells at different times after adoptive transfer. A. 18h post 
adoptive transfer. B. 48h post adoptive transfer. C.72h post adoptive transfer. 
Macrophages: F4/80+CD11b+Gr-1-; Dendritic cells CD11c+CD11b+Gr-1-. 
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Figure 14. Regulation of MDSC function by hypoxia.  
MDSC were isolated from spleens of CT26 tumor-bearing mice and cultured in medium 
containing 10 ng/ml GM-CSF and 25% CT26 TCCM under normoxic and hypoxic (1% O2) 
conditions using a hypoxic chamber. A. Expression of NOX subunits was evaluated in triplicates 
after 2 days. B. Cells were collected after 3 days of culture and DCFDA intensity was measured 
within the Gr-1+CD11b+ population. Typical result of three performed experiments is shown. C. 
Expression of argI and inos was evaluated in MDSC after 24 hr and 48 hr incubation.  D. MDSC 
were cultured for 48 hr under normoxic or hypoxic conditions and their ability to suppress 
proliferation of anti-CD3/CD28 stimulated splenocytes was evaluated 
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FIGURE 15. Regulation of MDSC differentiation by hypoxia 
A. MDSC were cultured for 5 days with GM-CSF (10 ng/ml) and 25% TCCM in normoxia or 
hypoxia, then fixed and stained with H&E. Magnification x 400. B. Phenotype of MDSC cultured 
for 5 days in hypoxia or normoxia. The proportion of cells with indicated phenotype were 
evaluated by flow cytometry. Cumulative results of 4 performed experiments are shown. * - 
statistical significant differences (p<0.05) between the groups. C-H. MDSC F4/80+ cells were 
isolated from MDSC cultured for 5 days and the expression of cytokines associated with M1 and 
M2 M! phenotypes (C. arginase; D. iNOS; E. IL-10;  F. IL-12; G. TGF-b; H. IL-6) were 
determined by real-time PCR. Results were compared to TAM isolated from tumor-bearing mice 
and peritoneal M! from naïve mice.  
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Figure 16. Consequences of HIF-1!  stabilization in MDSC properties.  
A. MDSC isolated from spleens of EL-4 tumor-bearing mice were cultured with GM-CSF (10 
ng/mL) in hypoxia for 4 hr or 16 hr. The level of HIF1-! was measured by Western blot. B-F. 
MDSC were treated with various concentrations of HIF-1! stabilizer DFO for 48 hr, then washed 
and used in the experiments. No effect of DFO on MDSC cell viability was observed at these 
concentrations (data not shown). B, C. Effect of DFO-treated MDSC on proliferation (B) and 
IFN-" production (C) of splenocytes stimulated with anti-CD3/CD28 antibodies. D, E. 
Expression of arg1, inos, gp91phox, and p47phox in DFO-treated MDSC for 48 hr treatment. 
Experiments were performed in triplicates and repeated two times with the same results. F. 
Percentage of F4/80+CD11b+ M# differentiated from MDSC treated with DFO for 5 days. 
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Figure 17. Evaluation of HIF-1!-deficient chimeric mice before and after tumor 
establishment.  
A. Expression of HIF-1! in HIF-1!fl/flCre+/- and HIF-1!fl/flCre-/- mice after treatment with poly I:C 
using real-time PCR. Experiments were performed in triplicates in three mice. B. Reconstitution 
of lethally irradiated CD45.1+ congenic mice with CD45.2+ bone marrow from HIF-1! deficient 
(HIF-1!flox/flox,Cre+/-) or wild-type (HIF-1!flox/flox, Cre-/-) mice. Blood of mice 2 weeks after bone 
marrow transfer was tested. C. CD45.1+ lethally irradiated recipients were reconstituted with 
CD45.2+ bone marrow cells from HIF-1!-deficient (-/-) or wild-type (+/+) mice. Two weeks later 
mice were inoculated s.c. with 5x105 EL-4 tumor cells. Three weeks after that, spleens were 
collected and cell phenotype was evaluated. For control, tumor-free recipients were used. Each 
group included three mice. Proportion and absolute number of MDSC (C), * -statistically 
significant (p<0.05) differences between mice reconstituted with HIF-1!-/- and HIF- 1!+/+ bone 
marrow. D. Splenocytes from tumor-free or EL4 tumor-bearing animals were labeled with 
DCFDA and fluorescence determined in the Gr-1+CD11b+ population. 
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Figure 18. Changes in MDSC function and differentiation induced by the tumor 
microenvironment require HIF-1!. CD45.1+ lethally irradiated recipients were reconstituted 
with bone marrow cells from HIF-1! knockout (KO) or wild-type (WT) CD45.2+ mice. Two 
weeks later mice were inoculated s.c. with 5x105 EL-4 tumor cells. Three weeks after that 
CD45.2+ HIF-1! WT or KO MDSC were isolated from spleens of tumor-bearing mice and then 
transferred into ascitis of congenic CD45.1+ mice. Twelve hours later, CD45.2+ CD11b+ donor 
cells were isolated and used in the following experiments. A. The MDSC were cultured with anti-
CD3/CD28 antibody-activated T cells (responder cells, Resp.) and their proliferation was 
measured. B. Expression of arg1 and inos was analyzed in the MDSC before and after adoptive 
transfer into the tumor milieu. Experiments were performed in triplicates. Each group includes 3 
mice. * - statistically significant (p<0.05) differences between the groups. C. ROS in MDSC after 
the adoptive transfer was determined with DCFDA. D. Percentage of macrophages and DCs in 
the population of CD11b+Gr-1-CD45.2+ donor cells 12 hr post-adoptive transfer. 
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Figure 19. Schematic of MDSC function and differentiation in tumor-bearing host. 
In lymphoid organs, MDSC retain a high level of NOX2 and increased ROS levels. This is 
associated with a little increase in NO production and arginase I activity. As a result these MDSC 
produce peroxynitrite and exert their effect only via close cell-cell contact with activated antigen-
specific T-cells, which induce antigen-specific T-cell tolerance. At the same time, these MDSC 
fail to suppress antigen non-specific activation of T cells. In contrast, at the tumor site, MDSC 
due to the effect of hypoxia via HIF-1!, dramatically up-regulate expression of inos and argI, 
which is associated with down-regulation of both NOX2 expression and ROS production. 
Because of these changes, MDSC acquire the ability to suppress antigen non-specific T cell 
functions, which contribute to the profound immune suppression observed within the tumor 
microenvironment. In addition, hypoxia via HIF-1! promotes differentiation of MDSC to 
immune suppressive TAM that further support the immune suppressive network. 
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DISCUSSION 
 
Existing evidence indicates that T lymphocytes in tumor-bearing hosts are 
exposed to multiple suppressive factors. T lymphocytes isolated from tumor tissues 
display a profound deficiency in their ability to respond to mitogenic stimulation and 
their effector functions are severely compromised. As example, T lymphocytes 
infiltrating rat gliomas displayed reduced CD3e and TCR expression compared to spleen 
cells When TILs were purified and stimulated with polyclonal mitogens ConA or anti-
CD3 in vitro, their proliferate capacity was markedly diminished compared to spleen T 
cells [153]. In contrast, T cells isolated from peripheral lymphoid organs seem to 
experience antigen specific anergy to tumor-associated antigens. Circulating CD8+ T 
cells, specific for melanoma-associated antigens, were unable to lyse melanoma target 
cells or produce cytokines while having capability to lyse Epstein-Barr virus-pulsed 
target cells or generate allogeneic responses [146]. Anti-CD3 antibody or PHA-induced 
T-cell responses were not affected in patients with metastatic kidney cancer (142). One 
possible explanation for these differences is that the tumor microenvironment contains a 
large number of different suppressive factors that are not present in the periphery (154).  
MDSC are a heterogeneous population of myeloid cells comprised of cells at 
various stages of differentiation. They prevent the activation and functionality of T 
lymphocytes, limiting the success of immunotherapy strategies aimed to eradicate 
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developing cancer cells. The suppression of lymphocytes caused by MDSC has been 
demonstrated by numerous laboratories. Elimination of MDSC improves the function of 
T lymphocytes to immunotherapeutic treatments and promoting regression of developing 
tumors in animal models (139,141,155).  
This work demonstrates a dual role played by MDSC in immune suppression in 
cancer depending on their location. In lymphoid organs, MDSC retain a high level of 
NOX2 and increased ROS levels. This is associated with a little increase in NO 
production and Arg I activity. The important role of ROS in spleen MDSC-mediated 
suppression of T cells is supported by ample evidence provided during recent years. 
(10,19,156-159). ROS was specifically implicated in antigen-specific T cell tolerance 
mediated by MDSC (10,159). Due to high generation of ROS, MDSC produce 
peroxynitrite and exert their effect only via close cell-cell contact with activated antigen-
specific T-cells, which induce antigen-specific T-cell tolerance (10). At the same time, 
these MDSC fail to suppress antigen non-specific activation of T cells. The up-regulation 
of ROS in MDSC is a common phenomenon observed in a variety of different tumor 
models (Figure 1A). Importantly, this phenomenon was observed in human MDSC as 
well (Figure 2). 
We tried to clarify the reason for the increase in ROS levels in these cells. 
Although cells can employ multiple mechanisms for ROS generation, in leukocytes the 
primary producer of ROS is NADPH oxidase (NOX2). NOX2 catalyzes the one-electron 
reduction of oxygen to superoxide anion using electrons supplied by NADPH. The 
importance of this enzyme can be observed in the severity of hereditary chronic 
granulomatous disease (CGD). CGD is caused by mutations in any of the genes that 
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encode the subunits of the oxidase and patients with CGD experience frequent life-
threatening infections during their lifetime (130). In leukocytes, increased ROS 
production in response to different stimuli is regulated primarily by activation of NOX2 
via assembly of the enzymatic complex on the cellular membrane after translocation from 
the cytoplasm. The response usually does not involve transcriptional regulation of 
subunits of the NADPH complex. However, our data demonstrate that in MDSC from 
tumor-bearing mice, the substantial increase in the expression of several NOX2 subunits 
contributes to the up-regulation of NOX2 activity and ROS production.  
Under the scenario of increased expression of NOX2 subunits, we believe that 
even slight stimulation of MDSC would result in a substantial production of ROS. An 
example of such stimuli could be an interaction of MDSC with activated T cells, 
endothelial cells, or fibroblasts in tissues. Under normal conditions, in the absence of 
injury, contact of myeloid cells with surrounding cells through adhesion molecules would 
result in a modest up-regulation of ROS (160). However, in a situation when NOX2 
expression is up-regulated in MDSC, the same interaction results in dramatic increase in 
ROS production in these cells. This may explain a previous report that direct cell-cell 
contact with antigen-specific CD8+ T cells caused substantially higher level of ROS in 
MDSC than in IMC causing inhibition of T cell responses (52). This phenomenon was 
proposed to be mediated by integrins CD11b, CD18, and CD29 as pre-treating MDSC 
with antibodies against these surface molecules abrogated the suppressive effect on the 
lymphocytes. In addition to contributing to their suppressive function, ROS have also 
been suggested to impede the differentiation of MDSC (127). MDSC with deleted 
gp91phox gene, thus lacking NOX2 activity, did not demonstrate increased ROS level 
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compared to IMC from naïve mice. Notably, lack of NOX2 activity blocked the 
suppressive activity of MDSC on CD8+ T cells and allowed MDSC to differentiate into 
mature myeloid cells in vitro. This strongly suggest that up-regulation of ROS in these 
cells in cancer is controlled by NOX2 activity.  
MDSC expansion in tumor-bearing hosts is mediated by various tumor-derived 
factors (44). STAT3 is arguably one of the main transcription factors responsible for 
MDSC accumulation in cancer. Signaling from many tumor-derived factors implicated in 
MDSC expansion ultimately converge in the Jak/STAT3 pathway (162,163). 
Consequently, MDSCs from tumor bearing mice have dramatically increased levels of 
phosphorylated STAT3 compared to IMC from naive mice (50). Exposure of 
hematopoietic progenitor cells to tumor-cell-conditioned medium resulted in the 
activation of STAT3 and was associated with an expansion of MDSCs in vitro, whereas 
inhibition of STAT3 in these cells abrogated the effect of tumor-derived factors on 
MDSC expansion (51). Ablation of STAT3 using conditional-mutant mice or selective 
inhibitors dramatically reduced the expansion of MDSCs and improved T-cell responses 
in tumor-bearing mice (50, 161). Thus, it appears that abnormal persistent activation of 
STAT3 in myeloid progenitors prevents differentiation of myeloid cells and is associated 
with increased proliferation and survival of myeloid progenitors, possibly through up-
regulation of STAT3-targeted genes like Bcl-xL, cyclin D1, c-myc, survivin (162) or 
S100A8 and S100A9 proteins (39). Due to such a prominent role of STAT3 in MDSC 
biology, it was tempting to speculate that STAT3 could be responsible for enhanced 
expression of NOX2. Our data suggests that STAT3 regulates expression of p47phox, 
arguably one of the main components of the NOX2 complex, by directly binding to the 
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p47phox gene promoter region. The experiments involving STAT3MT mice as well as over-
expression of STAT3 in ES cells further corroborates to the role of STAT3 in 
transcriptional regulation of p47phox and in addition suggest that gp91phox, the catalytic 
subunit of NOX2, is controlled by STAT3 through a similar process. Regulation of ROS 
in MDSC by STAT3 was further confirmed in experiments with JSI-124 (Fig. 7), a 
selective STAT3 inhibitor (135). Overall, this provides a direct link between the various 
tumor-derived factors affecting MDSC and the level of ROS in these cells.  
Inside tumor tissues, the tumor microenvironment convert MDSC into potent 
suppressor cells by up-regulating proteins involved in the metabolism of L-arginine. 
These enzymes (iNOS and Arg I) are known to be actively involved in T-cell suppression 
(164,165). Importantly, they do not require antigen-specific contact between MDSC and 
T cells to inhibit their function. This last observation makes biological sense, as tumor 
infiltrating lymphocytes are effector cells that have been activated in peripheral lymphoid 
organs and thus have already produced cytotoxic granules. Recognition of antigen by 
effector cells would lead to exocytosis of cytolytic enzymes (perforin and granzymes) 
resulting in the destruction of the target cell, or in this particular case the elimination of 
the MDSC. By circumventing the necessity of cell-to-cell interaction to activate their 
suppressive function, MDSC can inhibit T cell activity through down-regulation of CD3-
! re-expression, blocking CTL degranulation, and inducing T cell apoptosis, all of which 
are potential outcomes of iNOS and Arg 1 activity.  
In order to make a fair comparison of the function of MDSC from spleen and 
tumor sites, it was essential to ensure that we are indeed comparing cells with the same 
phenotype. We sorted MDSC based on the expression of Gr-1 and CD11b, two markers 
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that are considered hallmarks of MDSC. The expression of the macrophage cell marker 
F4/80 was slightly higher on tumor MDSC than on spleen cells; however, this F4/80 
expression was nowhere near the level expressed by TAMs. In addition, the MDSC we 
isolated from the tumor site and spleen had similar morphology and expression of other 
macrophage markers.  
The difference in suppressive activity between MDSC from tumor and spleen was 
quite substantial. While spleen MDSC contain a high level of ROS, and a relatively 
modest level of NO and Arg I activity (although it was still elevated by comparison with 
Gr-1+CD11b+ cells from naïve mice),  MDSC isolated from the tumor showed no 
increase in ROS over naïve Gr-1+CD11b+ IMC but a very high level of NO and arginase 
I. These biochemical disparities translated into fundamental differences in their ability to 
suppress T cells. Tumor-MDSC were not only more potent inhibitors of antigen-specific 
T-cell functions than spleen MDSC but also, in contrast to spleen MDSC, suppressed 
non-specific T cells. A recent study found that in spleens, granulocytic 
CD11b+Ly6G+Ly6Clow MDSC produce substantially higher level of ROS and a lower 
level of NO than monocytic CD11b+Ly6G-Ly6Chigh cells (19). It was possible that the 
composition of these MDSC subsets could be different in spleens and tumors which 
would explain the differences in functional activity of MDSC. However, the populations 
of MDSC in the spleen and tumor site contained similar ratios of granulocytic and 
monocytic sub-populations. Furthermore, experiments involving the direct transfer of 
spleen MDSC to the tumor microenvironment demonstrated that 4 hr was sufficient to 
cause dramatic changes in MDSC activity. These experiments also indicate that the 
observed differences were indeed specific for the relative MDSC population and not 
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caused by possible contamination of macrophages since the phenotype of MDSC was not 
changed within 4 hr after transfer (data not shown). 
The upregulation of Arg1 and iNOS by MDSC in the tumor site is a very rapid 
process and takes only hours to occur. One of the major factors that distinguish the tumor 
microenvironment from lymphoid organs is hypoxia. Tumor hypoxia is of great clinical 
concern as it can reduce the effectiveness of radiation therapy and lessen the efficacy of 
cytotoxic drugs (166-168). It appears that hypoxia also plays a critical role in the 
regulation of MDSC function by the tumor microenvironment. Our experiments have 
demonstrated that exposure of spleen MDSC to hypoxia could reproduce the effect of the 
tumor microenvironment on these cells by inducing a dramatic up-regulation of iNOS and 
Arg 1, decreasing the expression of NOX2 and ROS, and shifting MDSC-suppression 
from antigen-mediated to no requirement for antigen presentation. 
The major molecular mechanism of the hypoxia effect is mediated by the HIF-1 
transcription factor. In hematopoietic cells, HIF-1! is the predominant oxygen-sensitive 
subunit (169). Regulation of HIF-1 activity is mediated by posttranslational modification 
of the oxygen-dependent degradation domain (ODD) of HIF-1!. At oxygen levels above 
5%, hydroxylation of the proline residues 402 and 564 in the ODD of HIF-1! enables 
binding of the ubiquitination ligase von Hippel-Lindau tumor suppressor protein, which 
leads to degradation of HIF-1! by the proteosome. In contrast, at oxygen levels below 
5%, hydroxylation is inhibited leading to stabilization of HIF-1!. HIF-1! has been 
directly implicated in the up-regulation of iNOS (170) and arginase (171,172) in 
macrophages. HIF-1! has been shown to suppress oxidative phosphorylation and ROS 
production in mitochondria (173,174).  
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HIF-1! stabilization is not the only consequence of hypoxia exposure. One of the 
outcomes resulting from the metabolic changes induced by hypoxia is the accumulation 
of extracellular adenosine. Leukocytes express surface receptors capable of detecting 
adenosine, a class of these adenosine receptors, A2aR and A2bR, has been associated 
with immunosuppressive functions (175,176). The signaling cascade initiated through 
these receptors results in increased concentrations of cAMP, leading to attenuation of 
TCR-triggered T cell activation, TLR-triggered myeloid cell activation, and inhibition of 
T cell proliferation and cytokine production (IFN-", TNF). Another outcome originating 
due to tumor hypoxia is increased acidity in the tumor microenvironment. Under aerobic 
conditions, the catabolism of glucose concludes in the oxidation of pyruvate to CO2 and 
H2O in the mitochondria. However, in the situation when O2 is in short supply, glucose is 
reduced to lactate, resulting in the production and accumulation of lactic acid in the 
microenvironment of many cancer cell types (177). We investigated a potential role of 
both of these factors, adenosine and acidity, in regulation of MDSC function. However, 
neither treating MDSC with high adenosine concentrations nor lowering the pH in 
medium of cell cultures, altered the suppressive activity of MDSC (data not shown). 
These results, together with our data using mice reconstituted with a HIF-1!-deficient 
leukocyte compartment, strongly argue that HIF-1! directly mediates the shift in 
suppressive mechanisms employed by MDSC that was caused by the tumor-
microenvironment. 
MDSC have the potential to differentiate into macrophages and DCs (77,126), 
and hypoxia, acting via HIF-1!, appears to have a direct effect on MDSC differentiation. 
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Two days after our adoptive transfer experiment, more than 60% of MDSC that reached 
the spleen retained an immature phenotype while the rest of the cells differentiated 
evenly to macrop[hages and DCs. In contrast, MDSC transferred into tumor site 
differentiated much more rapidly, with most of the cells acquiring the phenotype of 
macrophages. In vitro culture of MDSC under hypoxic conditions recapitulated these 
findings. Stabilization of HIF-1! with DFO reproduced this effect, suggesting that HIF-
1! could be an important factor regulating the differentiation of MDSC to TAM. MDSC 
lacking HIF-1! did not differentiate into TAM within the tumor micoenvironemnt or 
under in vitro hypoxia, but interestingly acquired markers of DCs instead. It has been 
shown that in patients with cancer, tumors do contain small numbers of DCs. However, 
the DCs present do not express co-stimulatory molecules or adequate levels of MHC 
class II molecules and consequently are poor immune stimulators. For instance, it was 
shown that renal-cell carcinomas or tumors of the prostate contain DCs that express 
minimal levels of the costimulatory molecules CD80 and CD86 (178,179). Less than 1% 
of DCs isolated from basal-cell carcinomas expressed either CD80 or CD86 (180), while 
less than 10% of DCs isolated from colon carcinomas express CD80 or CD86. In the 
absence of an appropriate co-stimulatory signal for T cells, together with the lack of 
production of cytokines that are required for T-cell stimulation, any antigen presentation 
by tumor infiltrating DCs might result in the induction of tolerance. In support of this 
argument, DCs derived from colon-cancer tissue have been shown to be inducers of T-
cell anergy (181). Thus, it will be interesting to further explore in detail the phenotype of 
the DCs that differentiated from HIF-1! deficient MDSC inside the tumor; expression of 
co-stimulatory molecules, of MHC proteins, and of cytokines must be evaluated, as well 
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as their potential to induce an anti-tumor immune response. 
Although we did not explore this thoroughly, our data with HIF-1!-deficient mice 
indicate that this transcription factor may play an important role in MDSC expansion. 
Expansion of MDSC from HIF-1!-deficient progenitors in tumor-bearing mice was 
substantially lower than that from their HIF-1! wild-type counterparts. HIF-1! is 
critically important during embryonic hematopoiesis. HIF-1! knockout mice develop 
extensive hematopoietic pathologies and are embryonic lethal at day E10.5 due to neural 
tube defects, dilated vasculature, and hyperplastic myocardium; absence of VEGF is 
considered to be responsible for the defect. Involvement of HIF-1! in adult 
hematopoiesis within the bone marrow has not yet been fully proven, but some reports 
have pointed out the possible role of HIF-1! in myeloid cell differentiation. 
Differentiation of the macrophage THP-1 cell line or monocytes from peripheral blood 
caused up-regulation of HIF-1! and HIF-1", increasing HIF-1 transcriptional activity and 
expression of HIF-1 target genes (182). Another study has shown that CD34+ and 
CD133+ hematopoietic progenitor and stem cells express a stabilized cytoplasmic form of 
HIF-1! even under normoxic conditions. HIF-1! stabilization is also positively 
controlled by NADPH Oxidase-dependent production of ROS (183). In A549 cells, 
hypoxic upregulation of NOX1 and the subsequently augmented ROS generation 
activated HIF-1-dependent pathways (184). Furthermore, the upregulation of expression 
of mRNA encoding HIF1! is induced by other stimuli, such as signaling mediated by 
pro-inflammatory cytokines (185,186) insulin (187), thrombin, angiotensin II and 
platelet-derived growth factor (188). Therefore, the possibility exists that up regulation of 
HIF-1! target genes in myeloid progenitors may be mediated by ROS, tumor-secreted 
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cytokines, or by other inflammatory mediators, partially contributing to the systemic 
expansion of MDSC. Activation of HIF-1! by the aforementioned mechanisms in the 
periphery may not be sufficient to drive the differentiation of MDSC into mature cells; 
however, in the tumor, hypoxia likely induces multiple changes in MDSC, such as 
possible regulation of transcription factors (unpublished observations), which in 
combination with HIF-1! stabilization may promote differentiation to macrophages. It is 
also possible that hypoxia potently activates HIF-1! to a much greater extent than 
cytokines or inflammatory molecules can achieve, thus resulting in the activation of 
different sets of genes in the two compartments. 
Overall, this study may suggest a model of MDSC function and differentiation in 
cancer. Tumor-derived factors, via constitutive up-regulation of STAT3 transcription 
factors, induce an expansion of MDSC in BM of tumor-bearing hosts (39,50,130,189), 
results in an accumulation of MDSC in peripheral lymphoid organs and in the tumor site. 
In peripheral lymphoid organs, the accumulated MDSC contain high levels of NADPH 
Oxidase components and any stimuli, including contact with surrounding cells, makes the 
cells react with increased ROS productivity which contributes to the immunosuppressive 
activity of these cells. Thus, NOX2 could be an attractive target in therapeutic regulation 
of function of circulatory MDSC. In the tumor tissues, due to the effect of hypoxia via 
HIF-1!, MDSC dramatically up-regulate expression of iNOS and ArgI, which is 
associated with down-regulation of both NOX2 expression and ROS production. Because 
of these changes, MDSC acquire the ability to suppress antigen non-specific T cell 
functions, which contribute to the profound immune suppression observed within the 
tumor microenvironment. In addition, hypoxia via HIF-1! promotes differentiation of 
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MDSC to immune suppressive TAM that further support the immune suppressive 
network (Fig.18). Elucidation of this dual role of MDSC may not only help to understand 
the biology of tumor-associated immune suppression, but also suggest that any 
therapeutic interventions should take into account the effect of spatial location on the 
function of these cells.  
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